1
|
Di Tommaso S, Dourthe C, Dupuy JW, Dugot-Senant N, Cappellen D, Cazier H, Paradis V, Blanc JF, Le Bail B, Balabaud C, Bioulac-Sage P, Saltel F, Raymond AA. Spatial characterisation of β-catenin-mutated hepatocellular adenoma subtypes by proteomic profiling of the tumour rim. JHEP Rep 2024; 6:100913. [PMID: 38304236 PMCID: PMC10831953 DOI: 10.1016/j.jhepr.2023.100913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 09/06/2023] [Accepted: 09/09/2023] [Indexed: 02/03/2024] Open
Abstract
Background & Aims Hepatocellular adenomas (HCAs) are rare, benign, liver tumours classified at the clinicopathological, genetic, and proteomic levels. The β-catenin-activated (b-HCA) subtypes harbour several mutation types in the β-catenin gene (CTNNB1) associated with different risks of malignant transformation or bleeding. Glutamine synthetase is a surrogate marker of β-catenin pathway activation associated with the risk of malignant transformation. Recently, we revealed an overexpression of glutamine synthetase in the rims of exon 3 S45-mutated b-HCA and exon 7/8-mutated b-HCA compared with the rest of the tumour. A difference in vascularisation was found in this rim shown by diffuse CD34 staining only at the tumour centre. Here, we aimed to characterise this tumour heterogeneity to better understand its physiopathological involvement. Methods Using mass spectrometry imaging, genetic, and proteomic analyses combined with laser capture microdissection, we compared the tumour centre with the tumour rim and with adjacent non-tumoural tissue. Results The tumour rim harboured the same mutation as the tumour centre, meaning both parts belong to the same tumour. Mass spectrometry imaging showed different spectral profiles between the rim and the tumour centre. Proteomic profiling revealed the significant differential expression of 40 proteins at the rim compared with the tumour centre. The majority of these proteins were associated with metabolism, with an expression profile comparable with a normal perivenous hepatocyte expression profile. Conclusions The difference in phenotype between the tumour centres and tumour rims of exon 3 S45-mutated b-HCA and exon 7/8-mutated b-HCA does not depend on CTNNB1 mutational status. In a context of sinusoidal arterial pathology, tumour heterogeneity at the rim harbours perivenous characteristics and could be caused by a functional peripheral venous drainage. Impact and implications Tumour heterogeneity was revealed in β-catenin-mutated hepatocellular adenomas (b-HCAs) via the differential expression of glutamine synthase at tumour rims. The combination of several spatial approaches (mass spectrometry imaging, genetic, and proteomic analyses) after laser capture microdissection allowed identification of a potential role for peripheral venous drainage underlying this difference. Through this study, we were able to illustrate that beyond a mutational context, many factors can downstream regulate gene expression and contribute to different clinicopathological phenotypes. We believe that the combinations of spatial analyses that we used could be inspiring for all researchers wanting to access heterogeneity information of liver tumours.
Collapse
Affiliation(s)
- Sylvaine Di Tommaso
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
- Oncoprot Platform, TBM-Core US 005, Bordeaux, France
| | - Cyril Dourthe
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
- Oncoprot Platform, TBM-Core US 005, Bordeaux, France
| | | | | | - David Cappellen
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
- Bordeaux University Hospital Center, Tumor Bank and Tumor Biology Laboratory, Pessac, France
| | - Hélène Cazier
- Pathology Department, Henri Mondor AP-HP Hospital, Créteil, France
| | - Valérie Paradis
- Pathology Department, Henri Mondor AP-HP Hospital, Créteil, France
| | - Jean-Frédéric Blanc
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
- Department of Hepatology and Oncology, Bordeaux University Hospital, INSERM CIC 1401, Bordeaux, France
| | - Brigitte Le Bail
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
- Pathology Department, Bordeaux University Hospital, Bordeaux, France
| | - Charles Balabaud
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
| | - Paulette Bioulac-Sage
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
| | - Frédéric Saltel
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
- Oncoprot Platform, TBM-Core US 005, Bordeaux, France
| | - Anne-Aurélie Raymond
- Université Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
- Oncoprot Platform, TBM-Core US 005, Bordeaux, France
| |
Collapse
|
2
|
Guillon J, Le Borgne M, Milano V, Guédin-Beaurepaire A, Moreau S, Pinaud N, Ronga L, Savrimoutou S, Albenque-Rubio S, Marchivie M, Kalout H, Walker C, Chevallier L, Buré C, Largy E, Gabelica V, Mergny JL, Baylot V, Ferrer J, Idrissi Y, Chevret E, Cappellen D, Desplat V, Schelz Z, Zupkó I. New 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinazoline and 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinoline Derivatives: Synthesis and Biological Evaluation as Novel Anticancer Agents by Targeting G-Quadruplex. Pharmaceuticals (Basel) 2023; 17:30. [PMID: 38256866 PMCID: PMC10819771 DOI: 10.3390/ph17010030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2023] [Revised: 12/13/2023] [Accepted: 12/21/2023] [Indexed: 01/24/2024] Open
Abstract
The syntheses of novel 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinazolines 12 and 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinolines 13 are reported here in six steps starting from various halogeno-quinazoline-2,4-(1H,3H)-diones or substituted anilines. The antiproliferative activities of the products were determined in vitro against a panel of breast (MCF-7 and MDA-MB-231), human adherent cervical (HeLa and SiHa), and ovarian (A2780) cell lines. Disubstituted 6- and 7-phenyl-bis(3-dimethylaminopropyl)aminomethylphenyl-quinazolines 12b, 12f, and 12i displayed the most interesting antiproliferative activities against six human cancer cell lines. In the series of quinoline derivatives, 6-phenyl-bis(3-dimethylaminopropyl)aminomethylphenylquinoline 13a proved to be the most active. G-quadruplexes (G4) stacked non-canonical nucleic acid structures found in specific G-rich DNA, or RNA sequences in the human genome are considered as potential targets for the development of anticancer agents. Then, as small aza-organic heterocyclic derivatives are well known to target and stabilize G4 structures, their ability to bind G4 structures have been determined through FRET melting, circular dichroism, and native mass spectrometry assays. Finally, telomerase inhibition ability has been also assessed using the MCF-7 cell line.
Collapse
Affiliation(s)
- Jean Guillon
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Marc Le Borgne
- Small Molecules for Biological Targets Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, F-69373 Lyon, France
| | - Vittoria Milano
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Aurore Guédin-Beaurepaire
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Stéphane Moreau
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Noël Pinaud
- ISM—CNRS UMR 5255, Univ. Bordeaux, F-33405 Talence, France;
| | - Luisa Ronga
- E2S UPPA, CNRS, IPREM, Université de Pau et des Pays de l’Adour, F-64053 Pau, France;
| | - Solène Savrimoutou
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Sandra Albenque-Rubio
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | | | - Haouraa Kalout
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Charley Walker
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Louise Chevallier
- INSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, F-33076 Bordeaux, France; (J.G.); (V.M.); (A.G.-B.); (S.M.); (S.S.); (S.A.-R.); (H.K.); (C.W.); (L.C.)
| | - Corinne Buré
- CNRS, INSERM, IECB, US1, UAR 3033, Univ. Bordeaux, F-33600 Pessac, France;
| | - Eric Largy
- CNRS, INSERM, ARNA, UMR 5320, U1212, IECB, Univ. Bordeaux, F-33600 Pessac, France; (E.L.); (V.G.)
| | - Valérie Gabelica
- CNRS, INSERM, ARNA, UMR 5320, U1212, IECB, Univ. Bordeaux, F-33600 Pessac, France; (E.L.); (V.G.)
| | - Jean-Louis Mergny
- Ecole Polytechnique, Laboratoire d’Optique et Biosciences, CNRS, INSERM, Institut Polytechnique de Paris, F-91120 Palaiseau, France;
| | - Virginie Baylot
- Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, CNRS UMR7258, Inserm U1068, Univ. Aix Marseille, F-13009 Marseille, France;
| | - Jacky Ferrer
- INSERM UMR1312, BRIC, Bordeaux Institute of Oncology, Univ. Bordeaux, F-33076 Bordeaux, France; (J.F.); (Y.I.); (E.C.); (D.C.); (V.D.)
| | - Yamina Idrissi
- INSERM UMR1312, BRIC, Bordeaux Institute of Oncology, Univ. Bordeaux, F-33076 Bordeaux, France; (J.F.); (Y.I.); (E.C.); (D.C.); (V.D.)
| | - Edith Chevret
- INSERM UMR1312, BRIC, Bordeaux Institute of Oncology, Univ. Bordeaux, F-33076 Bordeaux, France; (J.F.); (Y.I.); (E.C.); (D.C.); (V.D.)
| | - David Cappellen
- INSERM UMR1312, BRIC, Bordeaux Institute of Oncology, Univ. Bordeaux, F-33076 Bordeaux, France; (J.F.); (Y.I.); (E.C.); (D.C.); (V.D.)
- Service Tumor Biology and Tumor Bank Laboratory, Groupe Hospitalier Bordeaux, CHU Bordeaux, F-33000 Bordeaux, France
| | - Vanessa Desplat
- INSERM UMR1312, BRIC, Bordeaux Institute of Oncology, Univ. Bordeaux, F-33076 Bordeaux, France; (J.F.); (Y.I.); (E.C.); (D.C.); (V.D.)
| | - Zsuzsanna Schelz
- Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary;
| | - István Zupkó
- Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary;
| |
Collapse
|
3
|
Cullot G, Boutin J, Fayet S, Prat F, Rosier J, Cappellen D, Lamrissi I, Pennamen P, Bouron J, Amintas S, Thibault C, Moranvillier I, Laharanne E, Merlio JP, Guyonnet-Duperat V, Blouin JM, Richard E, Dabernat S, Moreau-Gaudry F, Bedel A. Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9. Nat Commun 2023; 14:4072. [PMID: 37429857 DOI: 10.1038/s41467-023-39632-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 06/22/2023] [Indexed: 07/12/2023] Open
Abstract
The CRISPR-Cas9 system has revolutionized our ability to precisely modify the genome and has led to gene editing in clinical applications. Comprehensive analysis of gene editing products at the targeted cut-site has revealed a complex spectrum of outcomes. ON-target genotoxicity is underestimated with standard PCR-based methods and necessitates appropriate and more sensitive detection methods. Here, we present two complementary Fluorescence-Assisted Megabase-scale Rearrangements Detection (FAMReD) systems that enable the detection, quantification, and cell sorting of edited cells with megabase-scale loss of heterozygosity (LOH). These tools reveal rare complex chromosomal rearrangements caused by Cas9-nuclease and show that LOH frequency depends on cell division rate during editing and p53 status. Cell cycle arrest during editing suppresses the occurrence of LOH without compromising editing. These data are confirmed in human stem/progenitor cells, suggesting that clinical trials should consider p53 status and cell proliferation rate during editing to limit this risk by designing safer protocols.
Collapse
Affiliation(s)
- G Cullot
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
| | - J Boutin
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- CHU de Bordeaux, Biochemistry Laboratory, F-33000, Bordeaux, France
| | - S Fayet
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
| | - F Prat
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
| | - J Rosier
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
| | - D Cappellen
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- CHU de Bordeaux, Tumor Biology and Tumor Bank Laboratory, F-33000, Bordeaux, France
| | - I Lamrissi
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
| | - P Pennamen
- CHU de Bordeaux, department of medical genetics, F-33000, Bordeaux, France
| | - J Bouron
- CHU de Bordeaux, department of medical genetics, F-33000, Bordeaux, France
| | - S Amintas
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- CHU de Bordeaux, Tumor Biology and Tumor Bank Laboratory, F-33000, Bordeaux, France
| | - C Thibault
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
| | - I Moranvillier
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
| | - E Laharanne
- CHU de Bordeaux, Tumor Biology and Tumor Bank Laboratory, F-33000, Bordeaux, France
| | - J P Merlio
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- CHU de Bordeaux, Tumor Biology and Tumor Bank Laboratory, F-33000, Bordeaux, France
| | - V Guyonnet-Duperat
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- Vect'UB, vectorology platform, INSERM US 005-CNRS UAR 3427-TBM-Core, Bordeaux university, Bordeaux, France
| | - J M Blouin
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- CHU de Bordeaux, Biochemistry Laboratory, F-33000, Bordeaux, France
| | - E Richard
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- CHU de Bordeaux, Biochemistry Laboratory, F-33000, Bordeaux, France
| | - S Dabernat
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France
- CHU de Bordeaux, Biochemistry Laboratory, F-33000, Bordeaux, France
| | - F Moreau-Gaudry
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France.
- CHU de Bordeaux, Biochemistry Laboratory, F-33000, Bordeaux, France.
| | - A Bedel
- Bordeaux University, INSERM, BRIC, U1312, F-33000, Bordeaux, France.
- CHU de Bordeaux, Biochemistry Laboratory, F-33000, Bordeaux, France.
| |
Collapse
|
4
|
Guillard M, Caumont C, Marcorelles P, Merlio JP, Cappellen D, Uguen A. Performances of the Idylla GeneFusion Assay: contribution to a rapid diagnosis of targetable gene fusions in tumour samples. J Clin Pathol 2023:jcp-2023-208798. [PMID: 37185257 DOI: 10.1136/jcp-2023-208798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 04/11/2023] [Indexed: 05/17/2023]
Abstract
AIMS We aimed to evaluate the performances of the Idylla GeneFusion Assay (IGFA) designed to detect, in a single, rapid and fully automated assay, ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 gene fusions and MET exon 14 skipping in cancer samples. METHODS Based on a set of tumours enriched in cases with gene fusions, we applied the IGFA to tumour areas of various sizes and tumour cell contents. IGFA results were compared with those obtained with other methods (immunohistochemistry, fluorescent in situ hybridisation, DNA and RNA next-generation sequencing). RESULTS We selected 68 tumours: 49 cases with known gene fusions (8 ALK, 8 ROS1, 5 RET, 7 NTRK1, 3 NTRK2 and 6 NTRK3 ones) or MET exon 14 skipping mutations (12 cases) and 19 cases with no fusion and no MET mutation. We performed 128 IGFA tests on distinct tissue areas. The global sensitivity and specificity of the IGFA were, respectively, 62.82% and 99.2% with variations between molecular targets and tissue areas. Of note, 72.5% sensitivity and 98.79% specificity were obtained in 37 tissue areas fulfilling the manufacturer's recommendations (ie, at least 10% of tumour cells in at least 20 mm² of tissue area). The rate of non-conclusive results was higher in small samples with low percentages of tumour cells. CONCLUSIONS The IGFA could contribute to the rapid detection of targetable gene fusions and mutations, especially in context of rapidly growing cancers requiring urgent therapeutic choices.
Collapse
Affiliation(s)
- Matthieu Guillard
- Service d'Anatomie et Cytologie Pathologiques, CHRU Brest, Brest, France
| | - Charline Caumont
- Service de Biologie des Tumeurs, CHU Bordeaux, Pessac, France
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Université de Bordeaux, Pessac, France
| | - Pascale Marcorelles
- Service d'Anatomie et Cytologie Pathologiques, CHRU Brest, Brest, France
- LBAI, UMR1227 INSERM, Université de Bretagne Occidentale, Brest, France
| | - Jean-Philippe Merlio
- Service de Biologie des Tumeurs, CHU Bordeaux, Pessac, France
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Université de Bordeaux, Pessac, France
| | - David Cappellen
- Service de Biologie des Tumeurs, CHU Bordeaux, Pessac, France
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Université de Bordeaux, Pessac, France
| | - Arnaud Uguen
- Service d'Anatomie et Cytologie Pathologiques, CHRU Brest, Brest, France
- LBAI, UMR1227 INSERM, Université de Bretagne Occidentale, Brest, France
| |
Collapse
|
5
|
Cullot G, Amintas S, Karembé L, Prouzet-Mauléon V, Rébillard J, Boureau L, Cappellen D, Bedel A, Moreau-Gaudry F, Dulucq S, Dabernat S, Turcq B. Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements. CRISPR J 2023; 6:140-151. [PMID: 36912819 DOI: 10.1089/crispr.2022.0070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/14/2023] Open
Abstract
Advances in molecular medicine have placed nucleic acid detection methods at the center of an increasing number of clinical applications. Polymerase chain reaction (PCR)-based diagnostics have been widely adopted for their versatility, specificity, and sensitivity. However, recently reported clustered regularly interspaced short palindromic repeats-based methods have demonstrated equivalent to superior performance, with increased portability and reduced processing time and cost. In this study, we applied Specific High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) technology to the detection of oncogenic rearrangements. We implemented SHERLOCK for the detection of BCR::ABL1 mRNA, a hallmark of chronic myeloid leukemia (CML), and EGFR DNA oncogenic alleles, frequently detected in glioblastoma and non-small cell lung cancer (NSCLC). SHERLOCK enabled rapid, sensitive, and variant-specific detection of BCR::ABL1 and EGFR alterations. Compared with the gold-standard PCR-based methods currently used in clinic, SHERLOCK achieved equivalent to greater sensitivity, suggesting it could be a new tool in CML and NSCLC, to detect low level of molecular residual disease.
Collapse
Affiliation(s)
- Grégoire Cullot
- Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- Department of Biology, ETH Zurich, Zurich, Switzerland
| | - Samuel Amintas
- Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- Department of Tumor Biology and Tumor Library, CHU Bordeaux, Bordeaux, France
| | - Laura Karembé
- Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France
| | - Valérie Prouzet-Mauléon
- Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- CRISP'edit, TBMCore, CNRS UAR3427, INSERM US005, University of Bordeaux, Bordeaux, France
| | - Julie Rébillard
- Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France
| | - Lisa Boureau
- Laboratory of Hematology, CHU Bordeaux, Bordeaux, France
| | - David Cappellen
- Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- Department of Tumor Biology and Tumor Library, CHU Bordeaux, Bordeaux, France
| | - Aurélie Bedel
- Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- Department of Biochemistry and Molecular Biology, CHU Bordeaux, Bordeaux, France
| | - François Moreau-Gaudry
- Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- Department of Biochemistry and Molecular Biology, CHU Bordeaux, Bordeaux, France
| | - Stéphanie Dulucq
- Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- Laboratory of Hematology, CHU Bordeaux, Bordeaux, France
- Fi-LMC Group, Léon Bérard Center, Lyon, France
| | - Sandrine Dabernat
- Bordeaux Institute in Oncology-BRIC-BioGo Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- Department of Biochemistry and Molecular Biology, CHU Bordeaux, Bordeaux, France
| | - Béatrice Turcq
- Bordeaux Institute in Oncology-BRIC-MoTRIL Team, INSERM U1312, University of Bordeaux, Bordeaux, France
- CRISP'edit, TBMCore, CNRS UAR3427, INSERM US005, University of Bordeaux, Bordeaux, France
- Fi-LMC Group, Léon Bérard Center, Lyon, France
| |
Collapse
|
6
|
Ropio J, Prochazkova-Carlotti M, Batista R, Pestana A, Chebly A, Ferrer J, Idrissi Y, Cappellen D, Durães C, Boaventura P, Vinagre J, Azzi-Martin L, Poglio S, Cabeçadas J, Campos MA, Beylot-Barry M, Sobrinho-Simões M, Merlio JP, Soares P, Chevret E. Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas. Genes (Basel) 2023; 14:439. [PMID: 36833366 PMCID: PMC9956048 DOI: 10.3390/genes14020439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 02/05/2023] [Accepted: 02/06/2023] [Indexed: 02/11/2023] Open
Abstract
As a major cancer hallmark, there is a sustained interest in understanding the telomerase contribution to carcinogenesis in order to therapeutically target this enzyme. This is particularly relevant in primary cutaneous T-cell lymphomas (CTCL), a malignancy showing telomerase dysregulation with few investigative data available. In CTCL, we examined the mechanisms involved in telomerase transcriptional activation and activity regulation. We analyzed 94 CTCL patients from a Franco-Portuguese cohort, as well as 8 cell lines, in comparison to 101 healthy controls. Our results showed that not only polymorphisms (SNPs) located at the promoter of human telomerase reverse transcriptase (hTERT) gene (rs2735940 and rs2853672) but also an SNP located within the coding region (rs2853676) could influence CTCL occurrence. Furthermore, our results sustained that the post-transcriptional regulation of hTERT contributes to CTCL lymphomagenesis. Indeed, CTCL cells present a different pattern of hTERT spliced transcripts distribution from the controls, mostly marked by an increase in the hTERT β+ variants proportion. This increase seems to be associated with CTCL development and progression. Through hTERT splicing transcriptome modulation with shRNAs, we observed that the decrease in the α-β+ transcript induced a decrease in the cell proliferation and tumorigenic capacities of T-MF cells in vitro. Taken together, our data highlight the major role of post-transcriptional mechanisms regulating telomerase non canonical functions in CTCL and suggest a new potential role for the α-β+ hTERT transcript variant.
Collapse
Affiliation(s)
- Joana Ropio
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
- Institute of Biomedical Sciences of Abel Salazar, Porto University, 4050-313 Porto, Portugal
- Faculty of Veterinary Medicine, Lusófona University, 1749-024 Lisbon, Portugal
| | | | - Rui Batista
- Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
- Faculty of Medicine, Porto University, 4200-319 Porto, Portugal
| | - Ana Pestana
- Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
- Faculty of Medicine, Porto University, 4200-319 Porto, Portugal
| | - Alain Chebly
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
- Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut 1104 2020, Lebanon
- Higher Institute of Public Health, Saint Joseph University, Beirut 1104 2020, Lebanon
| | - Jacky Ferrer
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
| | - Yamina Idrissi
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
| | - David Cappellen
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
- Tumor Bank and Tumor Biology Laboratory, Bordeaux University Hospital, 33075 Bordeaux, France
| | - Cecília Durães
- Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
| | - Paula Boaventura
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
| | - João Vinagre
- Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
| | - Lamia Azzi-Martin
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
- UFR des Sciences Médicales, Bordeaux University, 33076 Bordeaux, France
| | - Sandrine Poglio
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
| | - José Cabeçadas
- Dermatology Departement, Instituto Português de Oncologia de Lisboa (IPO-L), 1099-023 Lisbon, Portugal
| | - Manuel António Campos
- Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
- Faculty of Medicine, Porto University, 4200-319 Porto, Portugal
- Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E., Dermatology Departement, 4434-502 Vila Nova de Gaia, Portugal
| | - Marie Beylot-Barry
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
- Dermatology Department, Bordeaux University Hospital, 33075 Bordeaux, France
| | - Manuel Sobrinho-Simões
- Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
- Faculty of Medicine, Porto University, 4200-319 Porto, Portugal
- Department of Pathology, Faculty of Medicine, Porto University, 4200-319 Porto, Portugal
| | - Jean-Philippe Merlio
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
- Tumor Bank and Tumor Biology Laboratory, Bordeaux University Hospital, 33075 Bordeaux, France
| | - Paula Soares
- Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal
- Faculty of Medicine, Porto University, 4200-319 Porto, Portugal
- Department of Pathology, Faculty of Medicine, Porto University, 4200-319 Porto, Portugal
| | - Edith Chevret
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France
| |
Collapse
|
7
|
Behnke A, Cayre A, De Maglio G, Giannini G, Habran L, Tarsitano M, Chetta M, Cappellen D, Lespagnol A, Le Naoures C, Massazza G, Destro A, Bonzheim I, Rau A, Battmann A, Kah B, Watkin E, Hummel M. FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC. Pathol Oncol Res 2023; 29:1610707. [PMID: 36798672 PMCID: PMC9927408 DOI: 10.3389/pore.2023.1610707] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Accepted: 01/11/2023] [Indexed: 02/04/2023]
Abstract
Accurate testing for epidermal growth factor receptor (EGFR) variants is essential for informing treatment decisions in non-small cell lung cancer (NSCLC). Automated diagnostic workflows may allow more streamlined initiation of targeted treatments, where appropriate, while comprehensive variant analysis is ongoing. FACILITATE, a real-world, prospective, multicenter, European study, evaluated performance and analytical turnaround time of the Idylla™ EGFR Mutation Test compared with local reference methods. Sixteen sites obtained formalin-fixed paraffin-embedded biopsy samples with ≥ 10% neoplastic cells from patients with NSCLC. Consecutive 5 μm sections from patient samples were tested for clinically relevant NSCLC-associated EGFR variants using the Idylla™ EGFR Mutation Test and local reference methods; performance (concordance) and analytical turnaround time were compared. Between January 2019 and November 2020, 1,474 parallel analyses were conducted. Overall percentage agreement was 97.7% [n = 1,418; 95% confidence interval (CI): 96.8-98.3], positive agreement, 87.4% (n = 182; 95% CI: 81.8-91.4) and negative agreement, 99.2% (n = 1,236; 95% CI: 98.5-99.6). There were 38 (2.6%) discordant cases. Ninety percent of results were returned with an analytical turnaround time of within 1 week using the Idylla™ EGFR Mutation Test versus ∼22 days using reference methods. The Idylla™ EGFR Mutation Test performed well versus local methods and had shorter analytical turnaround time. The Idylla™ EGFR Mutation Test can thus support application of personalized medicine in NSCLC.
Collapse
Affiliation(s)
- Anke Behnke
- Charité-Universitätsmedizin Berlin, Institute of Pathology and Berlin Institute of Health, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Anne Cayre
- Département de Pathologie, Centre Jean-Perrin, Clermont-Ferrand, France
| | - Giovanna De Maglio
- Azienda Sanitaria Universitaria Friuli Centrale, Pathology Department, Santa Maria della Misericordia Hospital, Udine, Italy
| | - Giuseppe Giannini
- Department Molecular Medicine, Università di Roma La Sapienza, Rome, Italy
| | - Lionel Habran
- Anatomopathology Department, CHU Liège, Liège, Belgium
| | - Marina Tarsitano
- Di Laboratorio, A.O.R.N. Cardarelli, Medical Genetics Laboratory, and Ospedale Antonio Cardarelli, U.O.C. di Genetica Medica, Naples, Italy
| | - Massimiliano Chetta
- Di Laboratorio, A.O.R.N. Cardarelli, Medical Genetics Laboratory, and Ospedale Antonio Cardarelli, U.O.C. di Genetica Medica, Naples, Italy
| | - David Cappellen
- Service de Biologie des Tumeurs, Centre Hospitalier Universitaire de Bordeaux, Hôpital du Haut Lévêque, Pessac, France
| | - Alexandra Lespagnol
- CHU de Rennes, Laboratoire de Génétique Somatique des Cancers, Rennes, France
| | - Cecile Le Naoures
- CHU de Rennes, Service d’Anatomie et Cytologie Pathologiques, Rennes, France
| | - Gabriella Massazza
- Dipartimento Medicina di Laboratorio Anatomia Patologica, ASST Papa Giovanni XXIII, Bergamo, BG, Italy
| | - Annarita Destro
- Pathology Department, Humanitas Clinical and Research Center—IRCCS, Milan, Italy
| | - Irina Bonzheim
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany
| | - Achim Rau
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany
| | - Achim Battmann
- Institut für Pathologie und Zytodiagnostik am Krankenhaus Nordwest, Frankfurt, Germany
| | - Bettina Kah
- Institut für Hämatopathologie Hamburg, Hamburg, Germany
| | | | - Michael Hummel
- Charité-Universitätsmedizin Berlin, Institute of Pathology and Berlin Institute of Health, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany,*Correspondence: Michael Hummel,
| |
Collapse
|
8
|
Peru S, Prochazkova-Carlotti M, Cherrier F, Velazquez J, Richard E, Idrissi Y, Cappellen D, Azzi-Martin L, Pham-Ledard A, Beylot-Barry M, Merlio JP, Poglio S. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. J Invest Dermatol 2022; 142:3243-3252.e10. [PMID: 35850209 DOI: 10.1016/j.jid.2022.06.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 06/08/2022] [Accepted: 06/10/2022] [Indexed: 01/05/2023]
Abstract
Cutaneous T-cell lymphoma (CTCL) such as Sézary syndrome or mycosis fungoides corresponds to an abnormal infiltration of T lymphocytes in the skin. CTCL cells have a heterogeneous phenotype and express cell adhesion molecules such as cutaneous lymphocyte antigen (CLA) supporting skin homing. The use of a mAb (HECA-452) against CLA significantly decreased transendothelial migration and survival of CTCL cells from patient samples and My-La cell line. The decrease of CLA expression by inhibition of its maturation enzyme, ST3 β-galactoside α-2,3-sialyltransferase 4, also impaired CTCL cell migration, proliferation, and survival. We confirmed in vivo that treatment with anti-CLA mAb decreased the tumorigenicity as well as dissemination of CTCL cells in different tissues compared with the control group. Our findings provide evidence of the involvement of CLA in CTCL cell migration and survival, supporting that CLA inhibition could represent an actionable therapy in patients with CTCL.
Collapse
Affiliation(s)
- Sara Peru
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France
| | | | - Floriane Cherrier
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France
| | - Joanne Velazquez
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France
| | - Elodie Richard
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France
| | - Yamina Idrissi
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France
| | - David Cappellen
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France; Tumor Bank and Tumor Biology Laboratory, Bordeaux University Hospital, Pessac, France
| | - Lamia Azzi-Martin
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France; UFR des Sciences Médicales, Bordeaux University, Bordeaux, France
| | - Anne Pham-Ledard
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France; Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - Marie Beylot-Barry
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France; Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - Jean-Philippe Merlio
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France; Tumor Bank and Tumor Biology Laboratory, Bordeaux University Hospital, Pessac, France
| | - Sandrine Poglio
- BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France.
| |
Collapse
|
9
|
Rahal F, Capdevielle C, Rousseau B, Yzotte J, Dupuy JW, Cappellen D, Chotard G, Ménard M, Charpentier J, Jecko V, Caumont C, Gimbert E, Grosset CF, Hagedorn M. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect. Neurooncol Adv 2022; 4:vdac018. [PMID: 35300150 PMCID: PMC8923007 DOI: 10.1093/noajnl/vdac018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Diffuse Midline Glioma, H3K27M-mutant (DMG) is a rare, highly aggressive pediatric tumor affecting the brainstem, and is one of the deadliest cancers. Currently available treatment options such as chemotherapy and radiotherapy do only modestly prolong survival. In this pathology, H3K27 mutations deregulate Polycomb Repressive Complex 2 (PRC2), including enzymatic activity of EZH2, which is therefore under investigation as a therapeutic target. Methods We used a chemical EZH2 inhibitor, GSK126, small interfering RNAs, and a CRISPR/Cas9 knockout approaches in a series of DMG tumor cell lines to investigate metabolic treatment responses by proteomic analysis. A combination strategy was elaborated and studied in primary and established DMG cells, spheroid 3D cultures, and in vivo in a chick chorio-allantoic membrane DMG assay and an orthotopic intracranial DMG mouse model. Results GSK126 shows significant (P < .05–.001) inhibitory effects in in vitro cell proliferation assays and induces apoptosis. Chemical targeting of EZH2 induced expression of proteins implicated in cholesterol metabolism. Low-dose GSK126 treatment together with statins revealed strong growth inhibition in combinatorial treatments, but not in single treatments, both in DMG cells in vitro, in DMG spheroid cultures, and in chick and mouse in vivo models (P < .05). All statistical tests were two-sided. Conclusions Our results reveal an unexpected GSK126-inducible sensitivity to cholesterol biosynthesis inhibitors in highly aggressive pediatric glioma that warrants further evaluation as treatment strategy. This combinatorial therapy should have few side effects because of the low doses used to achieve significant anti-tumor activity.
Collapse
Affiliation(s)
- Farah Rahal
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Inserm U1035, Bâtiment TP Zone Sud, Bordeaux, France
| | - Caroline Capdevielle
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Inserm U1035, Bâtiment TP Zone Sud, Bordeaux, France
| | - Benoit Rousseau
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Animalerie A2, Univ. Bordeaux, Bordeaux Cedex
| | - Julien Yzotte
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Animalerie A2, Univ. Bordeaux, Bordeaux Cedex
| | | | - David Cappellen
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Inserm U1035, Bâtiment TP Zone Sud, Bordeaux, France
| | - Guillaume Chotard
- Department of Neurosurgery, Hôpital Pellegrin, Bordeaux University Hospital, place Amélie Raba Léon, Bordeaux CEDEX, France
| | - Mélissa Ménard
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Inserm U1035, Bâtiment TP Zone Sud, Bordeaux, France
| | - Justine Charpentier
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Inserm U1035, Bâtiment TP Zone Sud, Bordeaux, France
| | - Vincent Jecko
- Department of Neurosurgery, Hôpital Pellegrin, Bordeaux University Hospital, place Amélie Raba Léon, Bordeaux CEDEX, France
| | - Charline Caumont
- Department of Pathology, Hôpital Pellegrin, Bordeaux University Hospital, place Amélie Raba Léon, Bordeaux CEDEX, France
| | - Edouard Gimbert
- Department of Neurosurgery, Hôpital Pellegrin, Bordeaux University Hospital, place Amélie Raba Léon, Bordeaux CEDEX, France
| | - Christophe F Grosset
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Inserm U1035, Bâtiment TP Zone Sud, Bordeaux, France
| | - Martin Hagedorn
- Univ Bordeaux, Campus de Carreire/Victoire, Sciences de la santé/Sciences de l'Homme, Bordeaux CEDEX, France
- Inserm U1035, Bâtiment TP Zone Sud, Bordeaux, France
| |
Collapse
|
10
|
Abstract
CRISPR-Cas9 is a highly promising technology for clinical development. However, this powerful tool can induce adverse genomic events. The off-target genotoxicity is well described, predictable, detectable, and resolved by the use of new generations of Cas9 nucleases with high fidelity. In contrast, the ON-target genotoxicity due to a DNA double-strand break at the targeted locus is still underestimated. Here, we review several genomic outcomes induced by CRISPR-Cas9 from the insertion/deletion of a few bases to megabase-scale rearrangements. We hope to highlight this barely detectable complex safety concern to promote further studies to understand the mechanisms better, to detect these unwanted events, and to prevent them for the safety management of future CRISPR-Cas9 clinical trials.
Collapse
Affiliation(s)
- Julian Boutin
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - David Cappellen
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Tumor Biology and Tumor Bank Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - Juliette Rosier
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
| | - Samuel Amintas
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Tumor Biology and Tumor Bank Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - Sandrine Dabernat
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - Aurélie Bedel
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - François Moreau-Gaudry
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| |
Collapse
|
11
|
Boutin J, Cappellen D, Rosier J, Amintas S, Dabernat S, Bedel A, Moreau-Gaudry F. ON-target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected. CRISPR J 2022; 5:19-30. [DOI: 10.1089/crispr.2021.0120] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Julian Boutin
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - David Cappellen
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Tumor Biology and Tumor Bank Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - Juliette Rosier
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
| | - Samuel Amintas
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Tumor Biology and Tumor Bank Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - Sandrine Dabernat
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - Aurélie Bedel
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| | - François Moreau-Gaudry
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux, France
- Biochemistry Laboratory, University Hospital Bordeaux, Bordeaux, France
| |
Collapse
|
12
|
Cappellen D, Catry-Thomas I, Castain C, Bioulac-Sage P. Hepatocellular adenoma with a double mutation HNF1A and IDH1 in a patient with Ollier disease. Liver Int 2021; 41:3009-3010. [PMID: 34582629 DOI: 10.1111/liv.15066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Affiliation(s)
- David Cappellen
- Inserm U1035, University Bordeaux, Tumor Biology Laboratory and Tumor Bank, University Hospital Bordeaux, Bordeaux, France
| | | | - Claire Castain
- Pathology Department, University Hospital Bordeaux, Bordeaux, France
| | | |
Collapse
|
13
|
Dousset L, Poizeau F, Robert C, Mansard S, Mortier L, Caumont C, Routier É, Dupuy A, Rouanet J, Battistella M, Greliak A, Cappellen D, Galibert MD, Allayous C, Lespagnol A, Gerard É, Kerneuzet I, Roy S, Dutriaux C, Merlio JP, Vergier B, Schrock AB, Lee J, Ali SM, Kammerer-Jacquet SF, Lebbé C, Beylot-Barry M, Boussemart L. Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy. JCO Precis Oncol 2021; 5:PO.21.00084. [PMID: 34950838 PMCID: PMC8691497 DOI: 10.1200/po.21.00084] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 08/04/2021] [Accepted: 11/06/2021] [Indexed: 12/15/2022] Open
Abstract
Emerging evidence suggests a correlation between the tumor mutational burden (TMB) and the response to programmed cell death-1 protein (PD-1) monotherapy across multiple cancer types. In skin cancers, as high TMB is mostly because of ultraviolet (UV) exposure, we hypothesized a correlation between the primary melanoma cutaneous location according to sun exposure and response to anti–PD-1 monotherapy. The location of the primary melanoma in a sun-exposed area can help choosing first-line advanced melanoma treatment.![]()
Collapse
Affiliation(s)
- Léa Dousset
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Florence Poizeau
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research], Rennes, France
| | - Caroline Robert
- Institut de Cancérologie Gustave Roussy et Université Paris-Saclay, Villejuif, France
| | - Sandrine Mansard
- Department of Medical Oncology, Estaing Hospital, Clermont-Ferrand, France
| | - Laurent Mortier
- Department of Dermatology, CHU de Lille, Université de Lille, Lille, France
| | - Charline Caumont
- Department of Tumor Pathology and Tumor Bank, University Hospital of Bordeaux, France
- INSERM U1053, UMR Bariton, Bordeaux University, Bordeaux, France
| | - Émilie Routier
- Institut de Cancérologie Gustave Roussy et Université Paris-Saclay, Villejuif, France
| | - Alain Dupuy
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research], Rennes, France
| | - Jacques Rouanet
- Department of Medical Oncology, Estaing Hospital, Clermont-Ferrand, France
| | - Maxime Battistella
- Department of Pathology, AP-HP, Saint-Louis University Hospital, Paris, France
| | - Anna Greliak
- Department of Dermatology, CHU de Lille, Université de Lille, Lille, France
| | - David Cappellen
- Department of Tumor Pathology and Tumor Bank, University Hospital of Bordeaux, France
| | - Marie-Dominique Galibert
- Hospital University of Rennes, Department of Molecular Genetics and Genomic, Rennes, France
- Université Rennes, CNRS, IGDR, UMR 6290, Rennes, France
| | - Clara Allayous
- Université de Paris, AP-HP Dermatology Department, INSERM U976, Saint-Louis Hospital, France
| | - Alexandra Lespagnol
- Hospital University of Rennes, Department of Molecular Genetics and Genomic, Rennes, France
- Université Rennes, CNRS, IGDR, UMR 6290, Rennes, France
| | - Émilie Gerard
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Inès Kerneuzet
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
| | - Séverine Roy
- Institut de Cancérologie Gustave Roussy et Université Paris-Saclay, Villejuif, France
| | - Caroline Dutriaux
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Jean-Philippe Merlio
- Department of Tumor Pathology and Tumor Bank, University Hospital of Bordeaux, France
| | - Beatrice Vergier
- Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | | | | | - Siraj M. Ali
- Foundation Medicine, Inc, Cambridge, MA
- EQRX Inc, Cambridge, MA
| | - Solène-Florence Kammerer-Jacquet
- Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, Rennes, France
- Department of Pathology, CHU de Rennes, Rennes, France
| | - Céleste Lebbé
- Université de Paris, AP-HP Dermatology Department, INSERM U976, Saint-Louis Hospital, France
| | - Marie Beylot-Barry
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Lise Boussemart
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
- Université Rennes, CNRS, IGDR, UMR 6290, Rennes, France
| |
Collapse
|
14
|
Boutin J, Rosier J, Cappellen D, Prat F, Toutain J, Pennamen P, Bouron J, Rooryck C, Merlio JP, Lamrissi-Garcia I, Cullot G, Amintas S, Guyonnet-Duperat V, Ged C, Blouin JM, Richard E, Dabernat S, Moreau-Gaudry F, Bedel A. CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells. Nat Commun 2021; 12:4922. [PMID: 34389729 PMCID: PMC8363739 DOI: 10.1038/s41467-021-25190-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 07/29/2021] [Indexed: 12/26/2022] Open
Abstract
CRISPR-Cas9 is a promising technology for gene therapy. However, the ON-target genotoxicity of CRISPR-Cas9 nuclease due to DNA double-strand breaks has received little attention and is probably underestimated. Here we report that genome editing targeting globin genes induces megabase-scale losses of heterozygosity (LOH) from the globin CRISPR-Cas9 cut-site to the telomere (5.2 Mb). In established lines, CRISPR-Cas9 nuclease induces frequent terminal chromosome 11p truncations and rare copy-neutral LOH. In primary hematopoietic progenitor/stem cells, we detect 1.1% of clones (7/648) with acquired megabase LOH induced by CRISPR-Cas9. In-depth analysis by SNP-array reveals the presence of copy-neutral LOH. This leads to 11p15.5 partial uniparental disomy, comprising two Chr11p15.5 imprinting centers (H19/IGF2:IG-DMR/IC1 and KCNQ1OT1:TSS-DMR/IC2) and impacting H19 and IGF2 expression. While this genotoxicity is a safety concern for CRISPR clinical trials, it is also an opportunity to model copy-neutral-LOH for genetic diseases and cancers.
Collapse
Affiliation(s)
- J Boutin
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- University Hospital Bordeaux, Biochemistry Laboratory, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - J Rosier
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - D Cappellen
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
- University Hospital Bordeaux, Tumor Biology and Tumor Bank Laboratory, Bordeaux, France
| | - F Prat
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - J Toutain
- Bordeaux University, MRGM INSERM U1211, CHU de Bordeaux, Service de Génétique Médicale, Bordeaux, France
| | - P Pennamen
- Bordeaux University, MRGM INSERM U1211, CHU de Bordeaux, Service de Génétique Médicale, Bordeaux, France
| | - J Bouron
- Bordeaux University, MRGM INSERM U1211, CHU de Bordeaux, Service de Génétique Médicale, Bordeaux, France
| | - C Rooryck
- Bordeaux University, Bordeaux, France
- Bordeaux University, MRGM INSERM U1211, CHU de Bordeaux, Service de Génétique Médicale, Bordeaux, France
| | - J P Merlio
- Bordeaux University, Bordeaux, France
- University Hospital Bordeaux, Tumor Biology and Tumor Bank Laboratory, Bordeaux, France
- INSERM U1053, Bordeaux Research in Translational Oncology, Bordeaux, France
| | - I Lamrissi-Garcia
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - G Cullot
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - S Amintas
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
- University Hospital Bordeaux, Tumor Biology and Tumor Bank Laboratory, Bordeaux, France
| | - V Guyonnet-Duperat
- INSERM US 005-CNRS UMS 342-TBM-Core, Bordeaux University, Bordeaux, France
| | - C Ged
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- University Hospital Bordeaux, Biochemistry Laboratory, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - J M Blouin
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- University Hospital Bordeaux, Biochemistry Laboratory, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - E Richard
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- University Hospital Bordeaux, Biochemistry Laboratory, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - S Dabernat
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- University Hospital Bordeaux, Biochemistry Laboratory, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| | - F Moreau-Gaudry
- Bordeaux University, Bordeaux, France.
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France.
- University Hospital Bordeaux, Biochemistry Laboratory, Bordeaux, France.
- Laboratory of Excellence, Gr-Ex, Bordeaux, France.
- INSERM US 005-CNRS UMS 342-TBM-Core, Bordeaux University, Bordeaux, France.
| | - A Bedel
- Bordeaux University, Bordeaux, France
- INSERM U1035, Biotherapy of Genetic Diseases, Inflammatory disorders and Cancers, Bordeaux, France
- University Hospital Bordeaux, Biochemistry Laboratory, Bordeaux, France
- Laboratory of Excellence, Gr-Ex, Bordeaux, France
| |
Collapse
|
15
|
Bocciarelli C, Caumont C, Samaison L, Cariou M, Aline-Fardin A, Doucet L, Roudié J, Terris B, Merlio JP, Marcorelles P, Cappellen D, Uguen A. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. Hum Pathol 2021; 114:99-109. [PMID: 34019865 DOI: 10.1016/j.humpath.2021.05.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Revised: 05/07/2021] [Accepted: 05/11/2021] [Indexed: 12/17/2022]
Abstract
Targetable kinase fusions are extremely rare (<1%) in colorectal cancers (CRCs), making their diagnosis challenging and often underinvestigated. They have been shown particularly frequently among MSI-High, BRAF/KRAS/NRAS wild-type CRCs with MLH1 loss (MLH1loss MSI-High wild-type). We searched for NTRK1, NTRK2, NTRK3, ALK, ROS1, BRAF, RET, and NRG1 kinase fusions in CRCs using methods easy-to-implement in pathology laboratories: immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and fully automated real-time PCR targeted analyses. RNA-sequencing analyses were used for confirmation. Among 84 selected MLH1 deficient (IHC) CRCs cases, MLH1loss MSI-High wild-type CRCs consisted first in 19 cases after Idylla™ analyses and finally in 18 cases (21%) after RNA-sequencing (detection of one additional KRASG12D mutation). FISH (and when relevant, IHC) analyses concluded in 5 NTRK1, 3 NTRK3, 1 ALK, 2 BRAF, and 2 RET FISH positive tumors. ALK and NTRK1 rearranged tumors were IHC positive, but pan-TRK IHC was negative in the 3 NTRK3 FISH positive tumors. RNA-sequencing analyses confirmed 12 of 13 fusions with only one false positive RET FISH result. Finally, 12/18 (67%) of MLH1loss MSI-High wild-type CRCs contained targetable kinase fusions. Our study demonstrates the feasibility, but also the cost-effectiveness, of a multistep but rapid diagnostic strategy based on nonsequencing methods to identify rare and targetable kinase fusions in patients with advanced CRCs, as well as the high prevalence of these kinase fusions in MLH1loss MSI-High wild-type CRCs. Nevertheless, confirmatory RNA-sequencing analyses are necessary in case of low FISH positive nuclei percentage to rule out FISH false-positive results.
Collapse
Affiliation(s)
- Claire Bocciarelli
- CHU de la Martinique, Service d'anatomie et Cytologie Pathologiques, Fort-de-France, F-97261, France.
| | - Charline Caumont
- CHU Bordeaux, Department of Tumor Biology, Pessac, F-33600, France; Inserm U1053 BaRITOn, Univ Bordeaux, Bordeaux, F-33000, France.
| | | | - Mélanie Cariou
- Registre des Cancers Digestifs du Finistère EA7479 SPURBO, Université de Bretagne Occidentale Brest, F-29200, France.
| | - Aude Aline-Fardin
- CHU de la Martinique, Service d'anatomie et Cytologie Pathologiques, Fort-de-France, F-97261, France.
| | - Laurent Doucet
- CHRU Brest, Service d'anatomie et Cytologie Pathologiques, Brest, F-29200, France.
| | - Jean Roudié
- CHU de la Martinique, Service de Chirurgie Digestive, Fort-de-France, F-97261, France.
| | - Benoît Terris
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Service d'anatomie et Cytologie Pathologiques, Paris, F-75014, France.
| | - Jean-Philippe Merlio
- CHU Bordeaux, Department of Tumor Biology, Pessac, F-33600, France; Inserm U1053 BaRITOn, Univ Bordeaux, Bordeaux, F-33000, France.
| | - Pascale Marcorelles
- CHRU Brest, Service d'anatomie et Cytologie Pathologiques, Brest, F-29200, France.
| | - David Cappellen
- CHU Bordeaux, Department of Tumor Biology, Pessac, F-33600, France; Inserm U1053 BaRITOn, Univ Bordeaux, Bordeaux, F-33000, France.
| | - Arnaud Uguen
- CHU de la Martinique, Service d'anatomie et Cytologie Pathologiques, Fort-de-France, F-97261, France; Univ Brest, Inserm, CHU de Brest, LBAI, UMR1227, Brest, 29200, France.
| |
Collapse
|
16
|
Poetsch L, Bronnimann C, Loiseau H, Frénel JS, Siegfried A, Seizeur R, Gauchotte G, Cappellen D, Carpentier C, Figarella-Branger D, Eimer S, Meyronet D, Ducray F. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation. J Neurooncol 2020; 151:279-286. [PMID: 33205355 DOI: 10.1007/s11060-020-03662-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Accepted: 11/09/2020] [Indexed: 01/16/2023]
Abstract
BACKGROUND Approximately 10% of IDH-mutant gliomas harbour non-canonical IDH mutations (non-p.R132H IDH1 and IDH2 mutations). OBJECTIVE The aim of this study was to analyse the characteristics of non-canonical IDH-mutant gliomas. MATERIALS AND METHODS We retrospectively analysed the characteristics of 166 patients with non-canonical IDH mutant gliomas and compared them to those of 155 consecutive patients with IDH1 p.R132H mutant gliomas. RESULTS The median age at diagnosis was 38 years in patients with non-canonical IDH mutant gliomas and 43 years in glioma patients with IDH1 p.R132H-mutant tumours. Family history of cancer was more frequent among glioma patients harbouring non-canonical IDH mutations than in patients with IDH1 p.R132H mutations (22.2% vs 5.1%; P < 0.05). Tumours were predominantly localised in the frontal lobe regardless of the type of IDH mutation. Compared to IDH1 p.R132H-mutant gliomas, tumours with non-canonical IDH mutations were more frequently found in the infratentorial region (5.5% vs 0%; P < 0.05) and were often multicentric (4.8% vs 0.9%; P < 0.05). Compared to IDH1 P.R132H-mutant gliomas, tumours with non-canonical IDH1 mutations were more frequently astrocytomas (65.6% vs 43%, P < 0.05), while those with IDH2 mutations were more frequently oligodendrogliomas (85% vs 48.3%; P < 0.05). The median overall survival was similar in patients with IDH1 p.R132H-mutant gliomas and patients with non-canonical IDH-mutant gliomas. CONCLUSION Gliomas with non-canonical IDH mutations have distinct radiological and histological characteristics. The presence of such tumours seems to be associated with genetic predisposition to cancer development.
Collapse
Affiliation(s)
- L Poetsch
- Service d'Oncologie Médicale, CHU de Bordeaux- Hôpital Saint André, 33000, Bordeaux, France
| | - C Bronnimann
- Service d'Oncologie Médicale, CHU de Bordeaux- Hôpital Saint André, 33000, Bordeaux, France.
| | - H Loiseau
- Service de Neurochirurgie B, CHU de Bordeaux - Hôpital Pellegrin, 33076, Bordeaux, France.,EA 7435 - IMOTION (Imagerie moléculaire et thérapies innovantes en oncologie) Université de Bordeaux, 33076, Bordeaux, France
| | - J S Frénel
- Institut de Cancérologie de l'Ouest, Centre René Gauducheau, 44800, Saint Herblain, France
| | - A Siegfried
- Service de Pathologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - R Seizeur
- Service de Neurochirurgie, Hôpital de la Cavale Blanche, CHRU de Brest, Université de Brest, Brest, France
| | - G Gauchotte
- Service d'Anatomie et Cytologie Pathologiques, CRB BB-0033-00035, CHRU de Nancy, INSERM U1256, Université de Lorraine, 54500, Vandœuvre-lès-Nancy, France
| | - D Cappellen
- U1035 Inserm - Biothérapie des Maladies Génétiques, Inflammatoires et Cancers (BMGIC), Univ. Bordeaux, 33076, Bordeaux, France.,Service de Biologie des Tumeurs, CHU de Bordeaux - Hôpital du Haut Lévêque, 33604, Pessac, France
| | - C Carpentier
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Epiniere, ICM, 75013, Paris, France
| | - D Figarella-Branger
- Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France
| | - S Eimer
- Service de Pathologie, CHU de Bordeaux, Hôpital Pellegrin, 33076, Bordeaux, France
| | - D Meyronet
- Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR 5286, Cancer Cell Plasticity department, Université Claude Bernard Lyon 1, Lyon, France.,Neuro-oncology Department, Hospices Civils de Lyon, Lyon, France
| | - F Ducray
- Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR 5286, Cancer Cell Plasticity department, Université Claude Bernard Lyon 1, Lyon, France.,Neuro-oncology Department, Hospices Civils de Lyon, Lyon, France
| | | |
Collapse
|
17
|
Ropio J, Chebly A, Ferrer J, Prochazkova‐Carlotti M, Idrissi Y, Azzi‐Martin L, Cappellen D, Pham‐Ledard A, Soares P, Merlio J, Chevret E. Reliable blood cancer cells' telomere length evaluation by qPCR. Cancer Med 2020; 9:3153-3162. [PMID: 32142223 PMCID: PMC7196062 DOI: 10.1002/cam4.2816] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 11/25/2019] [Accepted: 12/17/2019] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Telomere shortening is linked to a range of different human diseases, hence reliable measurement methods are needed to uncover such associations. Among the plethora of telomere length measurement methods, qPCR is reported as easy to conduct and a cost-effective approach to study samples with low DNA amounts. METHODS Cancer cells' telomere length was evaluated by relative and absolute qPCR methods. RESULTS Robust and reproducible telomere length measurements were optimized taking into account a careful reference gene selection and by knowing the cancer cells ploidy. qPCR data were compared to "gold standard" measurement from terminal restriction fragment (TRF). CONCLUSIONS Our study provides guidance and recommendations for accurate telomere length measurement by qPCR in cancer cells, taking advantage of our expertise in telomere homeostasis investigation in primary cutaneous T-cell lymphomas. Furthermore, our data emphasize the requirement of samples with both, high DNA quality and high tumor cells representation.
Collapse
Affiliation(s)
- Joana Ropio
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
- Porto UniversityInstitute of Biomedical Sciences of Abel SalazarPortoPortugal
- Instituto de Investigação e Inovação em SaúdePortoPortugal
- Institute of Molecular Pathology and ImmunologyUniversity of Porto (Ipatimup)Cancer Biology groupPortoPortugal
| | - Alain Chebly
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
- Faculty of MedicineMedical Genetics UnitSaint Joseph UniversityBeirutLebanon
| | - Jacky Ferrer
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
| | - Martina Prochazkova‐Carlotti
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
| | - Yamina Idrissi
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
| | - Lamia Azzi‐Martin
- Bordeaux UniversityUFR des Sciences MédicalesINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)BordeauxFrance
| | - David Cappellen
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
- Bordeaux University Hospital CenterTumor Bank and Tumor Biology LaboratoryPessacFrance
| | - Anne Pham‐Ledard
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
- Bordeaux University Hospital CenterDermatology DepartmentBordeauxFrance
| | - Paula Soares
- Instituto de Investigação e Inovação em SaúdePortoPortugal
- Institute of Molecular Pathology and ImmunologyUniversity of Porto (Ipatimup)Cancer Biology groupPortoPortugal
- Department of PathologyFaculty of MedicineUniversity of PortoPortoPortugal
| | - Jean‐Philippe Merlio
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
- Bordeaux University Hospital CenterTumor Bank and Tumor Biology LaboratoryPessacFrance
| | - Edith Chevret
- Bordeaux UniversityINSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn)Cutaneous Lymphoma Oncogenesis TeamBordeauxFrance
| |
Collapse
|
18
|
Pacaud A, Amintas S, Dousset L, Boussemart L, Dutriaux C, Cappellen D, Gérard E. Une réponse surprenante aux anti-MEK. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Poetsch L, Dehais C, Frénel J, Siegfried A, Lacomme S, Seizeur R, Larrieu-Ciron D, Cappellen D, Loussouarn D, Ferec C, Eimer S, Carpentier C, Sanson M, Delattre J, Figarella-Branger D, Ducray F, Bronnimann C. P04.12 Characteristics of IDH-mutant gliomas with non-canonical IDH mutations. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
About 10% of IDH-mutant gliomas harbor non-canonical IDH mutations (non-R132H IDH1 and IDH2 mutations). The aim of the present study was to analyze the characteristics of these gliomas in comparison to those of IDH1 R132H mutant gliomas.
MATERIAL AND METHODS
We retrospectively analyzed the characteristics of a multicentric series of 161 gliomas with non-canonical IDH mutations and compared them to those of consecutive series of 109 IDH1 R132H mutant gliomas. Medical, radiological and pathological were reviewed.
RESULTS
Median age at diagnosis was 35 years in gliomas with a non-canonical IDH1 mutation, 42 years in those with an IDH2 mutation and 44 years in those with an IDH1R132H mutation. A familial history of cancer was more frequent in gliomas with a non-canonical IDH mutation than in those with an IDH1 R132H mutation (22,3% vs 5,5%, p<0.05). In both IDH1 R132H-mutant and non-canonical IDH-mutant gliomas the most frequent location was the frontal lobe. Yet, compared to IDH1R132H-mutant gliomas those with a non-canonical IDH mutation had more frequently an infratentorial location (5,5% vs 0% p<0,05) and were more frequently multicentric (4,9%, versus 0.9%, p<0.05). Compared to IDH1R132H-mutant gliomas, gliomas with a non-canonical IDH1 mutation were more frequently astrocytomas (65.7% vs 45%, p<0.05) while those with an IDH2 mutation were more frequently oligodendrogliomas (82% vs 55%, p<0.05). The median overall survival in IDH1 R132H-mutant and non-canonical IDH-mutant gliomas was similar (122 versus 120 months).
CONCLUSION
Gliomas with non-canonical IDH mutations are associated with distinct clinical, radiological and histological characteristics. Their prognosis, however, is similar to that of gliomas with canonical IDH mutations.
Collapse
Affiliation(s)
| | | | - J Frénel
- Institut de Cancérologie de l’Ouest, Saint Herblain, France
| | | | | | | | | | | | - D Loussouarn
- Institut de Cancérologie de l’Ouest, Saint Herblain, France
| | | | - S Eimer
- CHU Pellegrin, BORDEAUX, France
| | | | | | | | | | - F Ducray
- Hopital Neurologique, Lyon, France
| | | | | |
Collapse
|
20
|
Cappellen D, Balabaud C, Bioulac-Sage P. A difficult case of β-catenin-mutated hepatocellular adenoma: a lesson for diagnosis. Histopathology 2018; 74:355-357. [PMID: 30184258 DOI: 10.1111/his.13751] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 08/23/2018] [Accepted: 09/02/2018] [Indexed: 02/06/2023]
Affiliation(s)
- David Cappellen
- Inserm, UMR1053 Bordeaux Research in Translational Oncology, BaRITOn, Université de Bordeaux, Bordeaux, France
| | - Charles Balabaud
- Inserm, UMR1053 Bordeaux Research in Translational Oncology, BaRITOn, Université de Bordeaux, Bordeaux, France
| | - Paulette Bioulac-Sage
- Inserm, UMR1053 Bordeaux Research in Translational Oncology, BaRITOn, Université de Bordeaux, Bordeaux, France
| |
Collapse
|
21
|
Mélard P, Idrissi Y, Andrique L, Poglio S, Prochazkova-Carlotti M, Berhouet S, Boucher C, Laharanne E, Chevret E, Pham-Ledard A, De Souza Góes AC, Guyonnet-Duperat V, Bibeyran A, Moreau-Gaudry F, Vergier B, Beylot-Barry M, Merlio JP, Cappellen D. Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes. Oncotarget 2018; 7:68734-68748. [PMID: 27626696 PMCID: PMC5356586 DOI: 10.18632/oncotarget.11930] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Accepted: 08/31/2016] [Indexed: 12/27/2022] Open
Abstract
Monoallelic 6p25.3 rearrangements associated with DUSP22 (Dual Specificity Phosphatase 22) gene silencing have been reported in CD30+ peripheral T-cell lymphomas (PTCL), mostly with anaplastic morphology and of cutaneous origin. However, the mechanism of second allele silencing and the putative tumor suppressor function of DUSP22 have not been investigated so far. Here, we show that the presence, in most individuals, of an inactive paralog hampers genetic and epigenetic evaluation of the DUSP22 gene. Identification of DUSP22-specific single-nucleotide polymorphisms haplotypes and fluorescence in situ hybridization and epigenetic characterization of the paralog status led us to develop a comprehensive strategy enabling reliable identification of DUSP22 alterations. We showed that one cutaneous anaplastic large T-cell lymphomas (cALCL) case with monoallelic 6p25.3 rearrangement and DUSP22 silencing harbored exon 1 somatic mutations associated with second allele inactivation. Another cALCL case carried an intron 1 somatic splice site mutation with predicted deleterious exon skipping effect. Other tested PTCL cases with 6p25.3 rearrangement exhibited neither mutation nor deletion nor methylation accounting for silencing of the non-rearranged DUSP22 allele, thus inactivated by a so far unknown mechanism. We also characterized the expression status of four DUSP22 splice variants and found that they are all silenced in cALCL cases with 6p25.3 breakpoints. We finally showed that restoring expression of the physiologically predominant isoform in DUSP22-deficient malignant T cells inhibits cellular expansion by stimulating apoptosis and impairs soft agar clonogenicity and tumorigenicity. This study therefore shows that DUSP22 behaves as a tumor suppressor gene in PTCL.
Collapse
Affiliation(s)
- Pierre Mélard
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Pathologie, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| | - Yamina Idrissi
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France
| | - Laetitia Andrique
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Biologie des Tumeurs-Tumorothèque, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| | - Sandrine Poglio
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France
| | - Martina Prochazkova-Carlotti
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France
| | - Sabine Berhouet
- Service de Biologie des Tumeurs-Tumorothèque, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| | - Cécile Boucher
- Service de Biologie des Tumeurs-Tumorothèque, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| | - Elodie Laharanne
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Biologie des Tumeurs-Tumorothèque, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| | - Edith Chevret
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France
| | - Anne Pham-Ledard
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, F-33000 Bordeaux, France
| | - Andréa Carla De Souza Góes
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, CEP 20550-013 Rio de Janeiro, Brazil
| | - Véronique Guyonnet-Duperat
- Plateforme de Vectorologie, Unité Mixte de Services (UMS TBM-Core), Centre National de la Recherche Scientifique (CNRS)- Institut National de la Santé et de la Recherche Médicale (Inserm)-Universitaire de Bordeaux, F-33076 Bordeaux, France
| | - Alice Bibeyran
- Plateforme de Vectorologie, Unité Mixte de Services (UMS TBM-Core), Centre National de la Recherche Scientifique (CNRS)- Institut National de la Santé et de la Recherche Médicale (Inserm)-Universitaire de Bordeaux, F-33076 Bordeaux, France
| | - François Moreau-Gaudry
- Plateforme de Vectorologie, Unité Mixte de Services (UMS TBM-Core), Centre National de la Recherche Scientifique (CNRS)- Institut National de la Santé et de la Recherche Médicale (Inserm)-Universitaire de Bordeaux, F-33076 Bordeaux, France.,Biothérapies des Maladies Génétiques et Cancers, Institut National de la Santé et de la Recherche Médicale (Inserm), U1035, Universitaire de Bordeaux, F-33076 Bordeaux, France
| | - Béatrice Vergier
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Pathologie, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| | - Marie Beylot-Barry
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, F-33000 Bordeaux, France
| | - Jean-Philippe Merlio
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Biologie des Tumeurs-Tumorothèque, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| | - David Cappellen
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1053, Universitaire de Bordeaux, F-33076 Bordeaux, France.,Service de Biologie des Tumeurs-Tumorothèque, Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, F-33604 Pessac, France
| |
Collapse
|
22
|
Cunha KS, Oliveira NS, Fausto AK, de Souza CC, Gros A, Bandres T, Idrissi Y, Merlio JP, de Moura Neto RS, Silva R, Geller M, Cappellen D. Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene. Genes (Basel) 2016; 7:genes7120133. [PMID: 27999334 PMCID: PMC5192509 DOI: 10.3390/genes7120133] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Revised: 11/29/2016] [Accepted: 12/07/2016] [Indexed: 12/25/2022] Open
Abstract
Neurofibromatosis 1 (NF1) is one of the most common genetic disorders and is caused by mutations in the NF1 gene. NF1 gene mutational analysis presents a considerable challenge because of its large size, existence of highly homologous pseudogenes located throughout the human genome, absence of mutational hotspots, and diversity of mutations types, including deep intronic splicing mutations. We aimed to evaluate the use of hybridization capture-based next-generation sequencing to screen coding and noncoding NF1 regions. Hybridization capture-based next-generation sequencing, with genomic DNA as starting material, was used to sequence the whole NF1 gene (exons and introns) from 11 unrelated individuals and 1 relative, who all had NF1. All of them met the NF1 clinical diagnostic criteria. We showed a mutation detection rate of 91% (10 out of 11). We identified eight recurrent and two novel mutations, which were all confirmed by Sanger methodology. In the Sanger sequencing confirmation, we also included another three relatives with NF1. Splicing alterations accounted for 50% of the mutations. One of them was caused by a deep intronic mutation (c.1260 + 1604A > G). Frameshift truncation and missense mutations corresponded to 30% and 20% of the pathogenic variants, respectively. In conclusion, we show the use of a simple and fast approach to screen, at once, the entire NF1 gene (exons and introns) for different types of pathogenic variations, including the deep intronic splicing mutations.
Collapse
Affiliation(s)
- Karin Soares Cunha
- Graduate Program in Pathology, School of Medicine, Universidade Federal Fluminense, Niterói 24033-900, Brazil.
- Department of Pathology, School of Medicine, Universidade Federal Fluminense, Niterói 24033-900, Brazil.
- Neurofibromatosis National Center (Centro Nacional de Neurofibromatose), Rio de Janeiro 20011-330, Brazil.
| | - Nathalia Silva Oliveira
- Anatomy Pathology Service, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói 24033-900, Brazil.
| | - Anna Karoline Fausto
- Anatomy Pathology Service, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói 24033-900, Brazil.
| | | | - Audrey Gros
- Service de Biologie des Tumeurs, Centre Hospitalier Universitaire de Bordeaux, Hôpital du Haut Lévêque, Pessac F-33604, France.
- Inserm (Institut National de la Santé et de la Recherche Médicale) U1053, Bordeaux Research in Translational Oncology (BaRITON) and University of Bordeaux, Bordeaux F-33076, France.
| | - Thomas Bandres
- Service de Biologie des Tumeurs, Centre Hospitalier Universitaire de Bordeaux, Hôpital du Haut Lévêque, Pessac F-33604, France.
| | - Yamina Idrissi
- Inserm (Institut National de la Santé et de la Recherche Médicale) U1053, Bordeaux Research in Translational Oncology (BaRITON) and University of Bordeaux, Bordeaux F-33076, France.
| | - Jean-Philippe Merlio
- Service de Biologie des Tumeurs, Centre Hospitalier Universitaire de Bordeaux, Hôpital du Haut Lévêque, Pessac F-33604, France.
- Inserm (Institut National de la Santé et de la Recherche Médicale) U1053, Bordeaux Research in Translational Oncology (BaRITON) and University of Bordeaux, Bordeaux F-33076, France.
| | | | - Rosane Silva
- Carlos Chagas Filho Biophysics Institute, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-599, Brazil.
| | - Mauro Geller
- Department of Immunology and Microbiology, School of Medicine, Centro Universitário Serra dos Órgãos, Teresópolis 25964-004, Brazil.
- Martagão Gesteira Child Care and Pediatrics Institute, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-912, Brazil.
| | - David Cappellen
- Service de Biologie des Tumeurs, Centre Hospitalier Universitaire de Bordeaux, Hôpital du Haut Lévêque, Pessac F-33604, France.
- Inserm (Institut National de la Santé et de la Recherche Médicale) U1053, Bordeaux Research in Translational Oncology (BaRITON) and University of Bordeaux, Bordeaux F-33076, France.
| |
Collapse
|
23
|
Floch P, Laur AM, Korolik V, Chrisment D, Cappellen D, Idrissi Y, Dubus P, Mégraud F, Lehours P. Characterisation of inflammatory processes in Helicobacter pylori-induced gastric lymphomagenesis in a mouse model. Oncotarget 2016; 6:34525-36. [PMID: 26439692 PMCID: PMC4741470 DOI: 10.18632/oncotarget.5948] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 09/08/2015] [Indexed: 12/16/2022] Open
Abstract
Gastric MALT lymphoma (GML) can be induced by Helicobacter pylori infection in BALB/c mice thymectomised at day 3 post-birth (d3Tx). This represented a unique opportunity to investigate the inflammatory process involved in the recruitment, proliferation and structuration of lymphoid infiltrates in the gastric mucosa of mice developing GML. Complementary molecular and proteomic approaches demonstrated that Th1 and Th2 cytokines were upregulated, along with activators/regulators of the lymphoid response and numerous chemokines. Interleukin-4, interferon γ, lymphotoxin-α and -β were significantly upregulated and correlated with the inflammatory scores for all the d3Tx mice. GML lesions in d3Tx mice infected with H. pylori were associated with the presence of the inflammatory response. The dysregulation of numerous members of the tumour necrosis factor superfamily was also evident and suggests that they could play an important role in GML pathology, especially in light of their ability to promote and control lymphocyte proliferation.
Collapse
Affiliation(s)
- Pauline Floch
- University of Bordeaux, Bacteriology Laboratory, Bordeaux, France.,Inserm U853, Bordeaux, France
| | - Amandine Marine Laur
- University of Bordeaux, Bacteriology Laboratory, Bordeaux, France.,Inserm U853, Bordeaux, France
| | - Victoria Korolik
- Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia
| | - Delphine Chrisment
- University of Bordeaux, Bacteriology Laboratory, Bordeaux, France.,Inserm U853, Bordeaux, France
| | | | | | | | - Francis Mégraud
- University of Bordeaux, Bacteriology Laboratory, Bordeaux, France.,Inserm U853, Bordeaux, France
| | - Philippe Lehours
- University of Bordeaux, Bacteriology Laboratory, Bordeaux, France.,Inserm U853, Bordeaux, France
| |
Collapse
|
24
|
Menguy S, Gros A, Pham-Ledard A, Battistella M, Ortonne N, Comoz F, Balme B, Szablewski V, Lamant L, Carlotti A, Lorton MH, de Muret A, Le Gall F, Franck F, Croue A, Cappellen D, Beylot-Barry M, Merlio JP, Vergier B. MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. J Invest Dermatol 2016; 136:1741-1744. [PMID: 27189828 DOI: 10.1016/j.jid.2016.04.018] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 04/05/2016] [Accepted: 04/12/2016] [Indexed: 10/21/2022]
Affiliation(s)
- Sarah Menguy
- INSERM U1053, Université Bordeaux, Bordeaux, France; Department of Pathology, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | - Audrey Gros
- INSERM U1053, Université Bordeaux, Bordeaux, France; Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | - Anne Pham-Ledard
- INSERM U1053, Université Bordeaux, Bordeaux, France; Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Maxime Battistella
- Department of Pathology, Assistance Publique des Hôpitaux de Paris, Hôpital Saint Louis, Université Paris, Paris, France
| | - Nicolas Ortonne
- Department of Pathology, Assistance Publique des Hôpitaux de Paris, Hôpital Henri Mondor, Creteil, France
| | - François Comoz
- Department of Pathology, Assistance Publique des Hôpitaux de Paris, Hôpital Saint Louis de Caen, Caen, France
| | - Brigitte Balme
- Department of Pathology, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France
| | - Vanessa Szablewski
- Department of Pathology, Centre Hospitalier Universitaire de Monpellier, Montpellier, France
| | - Laurence Lamant
- Department of Pathology, Institut Universitaire du Cancer-Toulouse Oncopôle, Toulouse, France
| | - Agnès Carlotti
- Department of Pathology, Assistance Publique des Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Marie-Hélène Lorton
- Department of Pathology, Centre Hospitalier Universitaire de Dijon, Dijon, France
| | - Anne de Muret
- Department of Pathology, Centre Hospitalier Universitaire de Tours, Tours, France
| | - François Le Gall
- Department of Pathology, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Frédéric Franck
- Department of Pathology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Anne Croue
- Department of Pathology, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - David Cappellen
- INSERM U1053, Université Bordeaux, Bordeaux, France; Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | - Marie Beylot-Barry
- INSERM U1053, Université Bordeaux, Bordeaux, France; Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Jean-Philippe Merlio
- INSERM U1053, Université Bordeaux, Bordeaux, France; Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, France.
| | - Béatrice Vergier
- INSERM U1053, Université Bordeaux, Bordeaux, France; Department of Pathology, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| |
Collapse
|
25
|
Furudoï A, Caumont C, Dutriaux C, Cappellen D, Goussot JF, Vergier B, Merlio C, Barberis C, Merlio JP, Gros A. Primary digestive melanoma in association with tubular adenoma: a case report illustrating the distinction from metastatic colonic melanoma. Hum Pathol 2015; 48:167-71. [PMID: 26616020 DOI: 10.1016/j.humpath.2015.09.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 09/02/2015] [Accepted: 09/16/2015] [Indexed: 02/03/2023]
Abstract
We report here an exceptional pattern of atypical lentiginous melanocytic proliferation within an adenoma, leading to focal lamina propria infiltration and pulmonary metastasis, which was considered as primary colonic mucosal melanoma (MM) in a Caucasian patient. Such case illustrates the diagnosis criteria required to differentiate primary MM from colonic metastasis of melanoma, including the absence of past history of other primary melanoma, a unique colonic and abdominal lesion with predominant features of in situ lentiginous MM and a very focal and unique invasive area without other digestive tract or abdominal localization. This tumor displayed a KIT exon 11 mutation leading to a unique combination of p.I571M and p.D572G deleterious amino acid changes. Such pattern also favors the diagnosis as KIT appears as a master oncogenic player in MM oncogenesis.
Collapse
Affiliation(s)
- Adeline Furudoï
- Cancer Biobank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, 33604, France
| | - Charline Caumont
- Cancer Biobank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, 33604, France; EA2406, Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, 33076, France
| | - Caroline Dutriaux
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, 33000, France
| | - David Cappellen
- Cancer Biobank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, 33604, France; EA2406, Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, 33076, France
| | - Jean-François Goussot
- Department of Pathology, Centre Hospitalier Universitaire de Bordeaux, Pessac 33604, France
| | - Béatrice Vergier
- EA2406, Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, 33076, France; Department of Pathology, Centre Hospitalier Universitaire de Bordeaux, Pessac 33604, France
| | | | - Christophe Barberis
- Gastroenterology Department, Maison de Santé Bagatelle, Talence, 33400, France
| | - Jean-Philippe Merlio
- Cancer Biobank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, 33604, France; EA2406, Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, 33076, France.
| | - Audrey Gros
- Cancer Biobank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Pessac, 33604, France; EA2406, Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, 33076, France
| |
Collapse
|
26
|
Fauconneau A, Pham-Ledard A, Cappellen D, Frison E, Prochazkova-Carlotti M, Parrens M, Dalle S, Joly P, Viraben R, Franck F, Ingen-Housz-Oro S, Giacchero D, Jullié ML, Vergier B, Merlio JP, Beylot-Barry M. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. Br J Dermatol 2015; 172:1547-1554. [DOI: 10.1111/bjd.13690] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/18/2015] [Indexed: 11/30/2022]
Affiliation(s)
- A. Fauconneau
- Department of Dermatology; Hôpital Haut Lévêque; Avenue de Magellan; 33604 PESSAC France
| | - A. Pham-Ledard
- Department of Dermatology; Hôpital Haut Lévêque; Avenue de Magellan; 33604 PESSAC France
- EA2406 Histology and Molecular Pathology of Tumors; Université de Bordeaux; Bordeaux France
| | - D. Cappellen
- EA2406 Histology and Molecular Pathology of Tumors; Université de Bordeaux; Bordeaux France
| | - E. Frison
- Pole de Sante Publique; Service d'information Médicale; CHU Bordeaux; Bordeaux France
| | | | - M. Parrens
- EA2406 Histology and Molecular Pathology of Tumors; Université de Bordeaux; Bordeaux France
- Department of Pathology; CHU Bordeaux; Bordeaux France
| | - S. Dalle
- Centre de Recherche en Cancérologie de Lyon; Université Claude Bernard Lyon 1; Hospices Civils de Lyon; Lyon France
| | - P. Joly
- Department of Dermatology; CHU Rouen; Rouen France
| | - R. Viraben
- Department of Dermatology; CHU Toulouse; Toulouse France
| | - F. Franck
- Department of Pathology; CHU Clermont-Ferrand; Université d'Auvergne; Clermont-Ferrand France
| | | | - D. Giacchero
- Department of Dermatology; CHU Nice; Nice France
| | - M.-L. Jullié
- Department of Pathology; CHU Bordeaux; Bordeaux France
| | - B. Vergier
- EA2406 Histology and Molecular Pathology of Tumors; Université de Bordeaux; Bordeaux France
- Department of Pathology; CHU Bordeaux; Bordeaux France
| | - J.-P. Merlio
- EA2406 Histology and Molecular Pathology of Tumors; Université de Bordeaux; Bordeaux France
- Tumor Bank and Department of Tumor Biology; CHU Bordeaux; Bordeaux France
| | - M. Beylot-Barry
- Department of Dermatology; Hôpital Haut Lévêque; Avenue de Magellan; 33604 PESSAC France
- EA2406 Histology and Molecular Pathology of Tumors; Université de Bordeaux; Bordeaux France
| |
Collapse
|
27
|
Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol 2015; 150:1173-9. [PMID: 25055137 DOI: 10.1001/jamadermatol.2014.821] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
IMPORTANCE The activating mutation of MYD88 L265P is a frequent feature of primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT), reported in up to 69% of the cases. Whether patients with MYD88 mutation display specific clinical and evolutive features has not been evaluated. OBJECTIVE To identify the clinical characteristics associated with MYD88 mutation, confirm its high prevalence, and evaluate its effect on prognosis in patients with PCLBCL-LT. DESIGN, SETTING, AND PARTICIPANTS A retrospective multicenter study was conducted using the medical records of patients from dermatology departments belonging to the French Study Group for Cutaneous Lymphomas. Sixty-one patients with a diagnosis of PCLBCL-LT made between 1988 and 2010 who were available for molecular study were included. Of these, 58 patients displaying interpretable results constituted the study group. Median follow-up was 33 months, and 39 patients (67%) were monitored until death. MAIN OUTCOMES AND MEASURES Clinical features (age, sex, number of skin lesions, tumor stage, and location as leg vs elsewhere), MYD88 mutation (allele-specific TaqMan polymerase chain reaction assay), treatment regimen, and outcome were recorded. Baseline characteristics and outcome were compared according to the status of MYD88. RESULTS The median age of the patients was 79 years, and 59% were female. Skin lesions were located on the leg in 76% of the cases. Thirty-four of 58 patients (59%) harbored the MYD88 L265P mutation. Patients had similar clinical characteristics at presentation regardless of their MYD88 status, except that those harboring the MYD88 mutation were older (P = .006) and had more frequent involvement of the leg (P = .008). Patients harboring the MYD88 mutation had 3- and 5-year-specific survival rates of 65.7% and 60.2% vs 85.4% and 71.7% in patients with the wild-type allele. The MYD88 mutation was significantly associated with shorter disease-specific survival in univariate (P = .03) and multivariate (odds ratio, 3.01; 95% CI, 1.03-8.78; P = .04) analysis. There was no significant difference between the groups in their treatment regimens. Considering overall survival, in univariate (P = .002) and multivariate (odds ratio, 2.94; 95% CI, 1.18-7.30; P = .02) analysis, MYD88 L265P mutation was an independent adverse prognostic factor. CONCLUSIONS AND RELEVANCE This study confirms the high prevalence of MYD88 L265P mutation in PCLBCL-LT and shows its association with shorter survival. The clinical effect of MYD88 mutation activating the nuclear factor-κB pathway supports the use of targeted therapies at the time of relapse after conventional therapies.
Collapse
Affiliation(s)
- Anne Pham-Ledard
- Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France2Department of Dermatology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - Marie Beylot-Barry
- Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France2Department of Dermatology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France3French Study Group for Cutaneous Lymphomas, France
| | - Coralie Barbe
- Unité d'Aide Méthodologique, Hôpital Robert Debré, Reims, France
| | - Marion Leduc
- Department of Clinical Research, Hôpital Maison Blanche, Centre Hospitalier Universitaire Reims, Reims, France
| | - Tony Petrella
- French Study Group for Cutaneous Lymphomas, France6Department of Pathology, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - Béatrice Vergier
- Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France3French Study Group for Cutaneous Lymphomas, France7Department of Pathology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - Fabian Martinez
- Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - David Cappellen
- Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France8Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - Jean-Philippe Merlio
- Equipe d'accueil 2406, Histology and Molecular Pathology of Tumors, Universitaire Bordeaux, Bordeaux, France3French Study Group for Cutaneous Lymphomas, France8Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire Bordeaux, Bordeaux, F
| | - Florent Grange
- French Study Group for Cutaneous Lymphomas, France9Department of Dermatology, Hôpital Robert Debré, Centre Hospitalier Universitaire Reims, Reims, France
| |
Collapse
|
28
|
Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F. La mutation MYD88 L265P est fréquente et a une valeur pronostique péjorative dans les lymphomes cutanés B diffus à grandes cellules de type jambe. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, Cappellen D, Vergier B, Martinez F, Grange F, Petrella T, Beylot-Barry M, Merlio JP. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 2014; 27:402-11. [PMID: 24030746 DOI: 10.1038/modpathol.2013.156] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Revised: 07/12/2013] [Accepted: 07/14/2013] [Indexed: 12/14/2022]
Abstract
Primary cutaneous large B-cell lymphoma, leg type has been individualized from nodal diffuse large B-cell lymphoma. The objective of this study was to screen primary cutaneous large B-cell lymphoma, leg type for genetic alterations recently described in nodal diffuse large B-cell lymphoma. Skin biopsies from 23 patients were analyzed for IRF4, BCL2, BCL6, and MYC expression. FISH testing was performed for BCL2, BCL6, MYC with separation probes and for CDKN2A and PRDM1/BLIMP1 deletion. Multiple sequential FISH analyses with up to six probes were performed to define samples with multiple cytogenetic alterations. MYD88 mutations were studied by Sanger sequencing. All cases but one displayed at least one genetic alteration (96%). Nine patients exhibited a single genetic mutation and 12 combined several alterations (52%). We observed a split for BCL2, BCL6, or MYC in 1/23, 6/23, and 3/23 of cases, respectively. No double-hit lymphoma was observed. CDKN2A deletion was detected by FISH in only 5/23 cases. BLIMP1 and/or 6q deletion was observed at a higher rate in 10/20 of cases. No correlation between rearrangement and immunohistochemical expression was found for BCL2 or MYC. FISH tracking of sequential hybridizations showed that several alterations were carried by the same nuclei. The p.L265P MYD88 mutation was found in 11/18 (61%) of cases. Contrary to most cutaneous lymphomas that rarely harbor primary genetic alteration of their nodal histological equivalent, primary cutaneous large B-cell lymphoma, leg type seems to be a 'cutaneous counterpart' of activated B-cell-like diffuse large B-cell lymphoma with a similar cytogenetic profile and a high rate of MYD88 oncogenic L265P mutation. This also suggests a common lymphomagenesis with NF-κB activation, strong IRF4 expression and terminal B-cell differentiation blockage. Our data support the use of therapies targeting NF-κB, as most patients displayed disease progression and resistance to conventional therapies.
Collapse
Affiliation(s)
- Anne Pham-Ledard
- 1] EA2406 Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, France [2] Dermatology Department, CHU Bordeaux, Bordeaux, France
| | | | - Laetitia Andrique
- EA2406 Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, France
| | - David Cappellen
- 1] EA2406 Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, France [2] Tumor Bank and Tumor Biology Laboratory, CHU Bordeaux, Bordeaux, France
| | | | - Fabian Martinez
- Tumor Bank and Tumor Biology Laboratory, CHU Bordeaux, Bordeaux, France
| | | | | | - Marie Beylot-Barry
- 1] EA2406 Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, France [2] Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - Jean-Philippe Merlio
- 1] EA2406 Histology and Molecular Pathology of Tumors, University of Bordeaux, Bordeaux, France [2] Tumor Bank and Tumor Biology Laboratory, CHU Bordeaux, Bordeaux, France
| |
Collapse
|
30
|
Boursault L, Haddad V, Vergier B, Cappellen D, Bellocq JP, Jouary T, Merlio JP. Homogénéité et conservation du statut BRAF entre mélanome primitif et métastases déterminées par immunohistochimie et biologie moléculaire. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, Cappellen D, Vergier B, Martinez F, Grange F, Petrella T, Beylot-Barry M, Merlio JP. Les lymphomes B diffus à grandes cellules de type jambe (LBDGC-TJ) sont porteurs de multiples anomalies génétiques en faveur d’une lymphomagenèse commune avec les lymphomes B diffus à grandes cellules de type ABC « Activated B-Cell » (LBDGC-ABC). Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Abstract
WNT5A, a member of the WNT family of secreted lipid-modified glycoproteins, is a critical regulator of a host of developmental processes, including limb formation, lung morphogenesis, intestinal elongation and mammary gland development. Altered WNT5A expression has been associated with a number of cancers. Interestingly, in certain types of cancers, such as hematological malignancies and colorectal carcinoma, WNT5A is inactivated and exerts a tumor suppressive function, while in other cancers, such as melanoma and gastric carcinoma, WNT5A is overexpressed and promotes tumor progression. The mechanism by which WNT5A achieves these distinct activities in cancers is poorly understood. Here, we provide evidence that the WNT5A gene produces two protein isoforms, WNT5A-long (WNT5A-L) and WNT5A-short (WNT5A-S). Amino-terminal sequencing and a WNT5A-L specific antibody demonstrate that the mature and secreted isoforms are distinct, with WNT5A-L carrying an additional 18 N-terminal amino acids. Biochemical analysis indicates that both purified proteins are similar with respect to their stability, hydrophobicity and WNT/β-catenin signaling activity. Nonetheless, modulation of these two WNT5A isoforms, either through ectopic expression or knockdown, demonstrates that they exert distinct activities in cancer cell lines: while WNT5A-L inhibits proliferation of tumor cell lines, WNT5A-S promotes their growth. Finally, we show that expression of these two WNT5A isoforms is altered in breast and cervix carcinomas, as well as in the most aggressive neuroblastoma tumors. In these cancers, WNT5A-L is frequently down-regulated, whereas WNT5A-S is found overexpressed in a significant fraction of tumors. Altogether, our study provides evidence that the distinct activities of WNT5A in cancer can be attributed to the production of two WNT5A isoforms.
Collapse
Affiliation(s)
- Matthieu Bauer
- Centre National de Recherche Scientifique-Université Paris, Institut de Cancérologie Gustave Roussy, Villejuif, France
- Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, United States of America
| | - Jean Bénard
- Centre National de Recherche Scientifique-Université Paris, Institut de Cancérologie Gustave Roussy, Villejuif, France
- Département de Pathologie et Biologie Médicales, Institut de Cancérologie Gustave Roussy, Villejuif, France
| | - Terry Gaasterland
- University of California San Diego and Scripps Institution of Oceanography, La Jolla, California, United States of America
| | - Karl Willert
- Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, United States of America
- * E-mail: (DC); (KW)
| | - David Cappellen
- Centre National de Recherche Scientifique-Université Paris, Institut de Cancérologie Gustave Roussy, Villejuif, France
- Centre Hospitalier Universitaire de Bordeaux, Université Bordeaux, Bordeaux, France
- Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux, Bordeaux, France
- * E-mail: (DC); (KW)
| |
Collapse
|
33
|
Boursault L, Haddad V, Vergier B, Cappellen D, Verdon S, Bellocq JP, Jouary T, Merlio JP. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One 2013; 8:e70826. [PMID: 23976959 PMCID: PMC3748080 DOI: 10.1371/journal.pone.0070826] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Accepted: 06/23/2013] [Indexed: 02/07/2023] Open
Abstract
BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melanoma and BRAFV600 mutations. In order to evaluate BRAF tumor heterogeneity between primary and metastatic site, we have evaluated the performance of immunohistochemistry (IHC) with an anti-BRAFV600E antibody in both localization by comparison with high resolution melting analysis followed by Sanger sequencing in a parallel blinded study. A total of 230 samples distributed as primary melanoma (n = 88) and different types of metastatic samples (n = 142) were studied in 99 patients with advanced or metastatic melanoma (stage III or IV). The prevalence of each BRAF mutation was c.1799T>A, BRAFV600E (45.2%), c.1799_1800TG>AA, BRAFV600E2 (3.0%), c.1798_1799GT>AA, BRAFV600K (3.0%), c.1801 A>G, BRAFK601E (1.3%), c.1789_1790CT>TC, BRAFL597S (0.4%), c.1780G>A, BRAFD594N (0.9%) respectively. IHC was positive in 109/112 samples harboring BRAFV600E/E2 mutations and negative in other cases. The cytoplasmic staining was either strongly positive in tumor cells of BRAFV600E mutated cases. It appeared strong brown, different from the vesicular grey cytoplasmic pigmentation of melanophages. Concordance between the two techniques was 96.4%. Sensitivity of IHC for detecting the BRAFV600E/E2 mutations was 97.3%, while specificity was 100%. Both our IHC and molecular study demonstrated homogeneity between primary and metastatic sites for BRAF status in melanoma. This study also provides evidence that IHC may be a cost-effective first-line method for BRAFV600E detection. Thereafter, molecular techniques should be used in negative, ambiguous or non-contributive cases.
Collapse
Affiliation(s)
| | - Véronique Haddad
- Tumor Bank and Tumor Biology Laboratory, CHU Bordeaux, Pessac, France
| | | | - David Cappellen
- Tumor Bank and Tumor Biology Laboratory, CHU Bordeaux, Pessac, France
| | - Severine Verdon
- Tumor Bank and Tumor Biology Laboratory, CHU Bordeaux, Pessac, France
| | | | - Thomas Jouary
- Department of Dermatology, CHU Bordeaux, Bordeaux, France
| | | |
Collapse
|
34
|
Toutain J, Prochazkova-Carlotti M, Cappellen D, Jarne A, Chevret E, Ferrer J, Idrissi Y, Pelluard F, Carles D, Maugey-Laulon B, Lacombe D, Horovitz J, Merlio JP, Saura R. Reduced placental telomere length during pregnancies complicated by intrauterine growth restriction. PLoS One 2013; 8:e54013. [PMID: 23326560 PMCID: PMC3543434 DOI: 10.1371/journal.pone.0054013] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Accepted: 12/05/2012] [Indexed: 11/19/2022] Open
Abstract
Objectives Recent studies have shown that telomere length was significantly reduced in placentas collected at delivery from pregnancies complicated by intrauterine growth restriction secondary to placental insufficiency. Placental telomere length measurement during ongoing pregnancies complicated by intrauterine growth restriction has never been reported. This was the main objective of our study. Methods In our center, late chorionic villus samplings were performed between 18 and 37 weeks of amenorrhea in 24 subjects with severe intrauterine growth restriction (cases) and in 28 subjects with other indications for prenatal diagnosis (controls). Placental insufficiency was assessed by histo-pathological examination. Relative measurement of telomere length was carried out prospectively by quantitative Fluorescent In Situ Hybridization using fluorescent Peptide Nucleic Acid probes on interphase nuclei obtained from long-term cultured villi and with an automated epifluorescent microscope. A quantitative Polymerase Chain Reaction technique was performed to confirm the quantitative Fluorescent In Situ Hybridization results. The number of copies of gene loci encoding the RNA template (hTERC) and the catalytic subunit (hTERT) of the enzyme complex telomerase were also estimated in these placentas by Fluorescent In Situ Hybridization. Results Mean fluorescence intensity of telomere probes estimated by quantitative Fluorescent In Situ Hybridization was significantly less for cases compared to controls (p<0.001). This result indicated that mean telomere length was significantly reduced in placentas during pregnancies complicated by intrauterine growth restriction. Reduced telomere length was confirmed by the quantitative Polymerase Chain Reaction technique. No copy number variation of the hTERC and hTERT loci was noticed for cases, or for controls. Conclusion This study clearly demonstrates a reduction of placental telomere length in ongoing pregnancies (from 18 to 37 weeks of amenorrhea) complicated by severe intrauterine growth restriction secondary to placental insufficiency.
Collapse
Affiliation(s)
- Jérôme Toutain
- EA 2406 Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Vu PY, Toutain J, Cappellen D, Delrue MA, Daoud H, El Moneim AA, Barat P, Montaubin O, Bonnet F, Dai ZQ, Philippe C, Tran CT, Rooryck C, Arveiler B, Saura R, Briault S, Lacombe D, Taine L. A homozygous balanced reciprocal translocation suggests LINC00237 as a candidate gene for MOMO (macrosomia, obesity, macrocephaly, and ocular abnormalities) syndrome. Am J Med Genet A 2012; 158A:2849-56. [PMID: 23034868 DOI: 10.1002/ajmg.a.35694] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2012] [Accepted: 08/29/2012] [Indexed: 11/10/2022]
Abstract
Macrosomia, obesity, macrocephaly, and ocular abnormalities syndrome (MOMO syndrome) has been reported in only four patients to date. In these sporadic cases, no chromosomal or molecular abnormality has been identified thus far. Here, we report on the clinical, cytogenetic, and molecular findings in a child of healthy consanguineous parents suffering from MOMO syndrome. Conventional karyotyping revealed an inherited homozygous balanced reciprocal translocation (16;20)(q21;p11.2). Uniparental disomy testing showed bi-parental inheritance for both derivative chromosomes 16 and 20. The patient's oligonucleotide array-comparative genomic hybridization profile revealed no abnormality. From the homozygous balanced reciprocal translocation (16;20)(q21;p11.2), a positional cloning strategy, designed to narrow 16q21 and 20p11.2 breakpoints, revealed the disruption of a novel gene located at 20p11.23. This gene is now named LINC00237, according to the HUGO (Human Genome Organization) nomenclature. The gene apparently leads to the production of a non-coding RNA. We established that LINC00237 was expressed in lymphocytes of control individuals while normal transcripts were absent in lymphocytes of our MOMO patient. LINC00237 was not ubiquitously expressed in control tissues, but it was notably highly expressed in the brain. Our results suggested autosomal recessive inheritance of MOMO syndrome. LINC00237 could play a role in the pathogenesis of this syndrome and could provide new insights into hyperphagia-related obesity and intellectual disability.
Collapse
Affiliation(s)
- Phi Yen Vu
- Univ. Bordeaux, Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Goes ACS, Cappellen D, Santos GC, Pirozhkova I, Lipinski M, Vassetzky Y, de Moura-Gallo CV. Loop domain organization of the p53 locus in normal and breast cancer cells correlates with the transcriptional status of the TP53 and the neighboring genes. J Cell Biochem 2011; 112:2072-81. [PMID: 21465532 DOI: 10.1002/jcb.23129] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
P53 is a tumor suppressor protein critical for genome integrity. Although its control at the protein level is well known, the transcriptional regulation of the TP53 gene is still unclear. We have analyzed the organization of the TP53 gene domain using DNA arrays in several breast cancer and control cell lines. We have found that in the control breast epithelial cell line, HB2, the TP53 gene is positioned within a relatively small DNA domain, encompassing 50 kb, delimited by two nuclear matrix attachment sites. Interestingly, this domain structure was found to be radically different in the studied breast cancer cell lines, MCF7, T47D, MDA-MB-231, and BT474, in which the domain size was increased and TP53 transcription was decreased. We propose a model in which the organization of the TP53 gene domain correlates with the transcriptional status of TP53 and neighboring genes.
Collapse
Affiliation(s)
- Andrea C S Goes
- Unité Mixte de Recherche 8126, Signalisation, Noyaux et Innovations en Cancérologie, Centre NaTional de la Recherche Scientifique, Institut de Cancérologie Gustave-Roussy, Université Paris-Sud 11, F-94805 Villejuif Cedex, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA, Stupack D, Nakagawara A, Rousseau R, Combaret V, Puisieux A, Valteau-Couanet D, Bénard J, Bernet A, Mehlen P. Netrin-1 acts as a survival factor for aggressive neuroblastoma. ACTA ACUST UNITED AC 2009; 206:833-47. [PMID: 19349462 PMCID: PMC2715117 DOI: 10.1084/jem.20082299] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Neuroblastoma (NB), the most frequent solid tumor of early childhood, is diagnosed as a disseminated disease in >60% of cases, and several lines of evidence support the resistance to apoptosis as a prerequisite for NB progression. We show that autocrine production of netrin-1, a multifunctional laminin-related molecule, conveys a selective advantage in tumor growth and dissemination in aggressive NB, as it blocks the proapoptotic activity of the UNC5H netrin-1 dependence receptors. We show that such netrin-1 up-regulation is a potential marker for poor prognosis in stage 4S and, more generally, in NB stage 4 diagnosed infants. Moreover, we propose that interference with the netrin-1 autocrine loop in malignant neuroblasts could represent an alternative therapeutic strategy, as disruption of this loop triggers in vitro NB cell death and inhibits NB metastasis in avian and mouse models.
Collapse
|
38
|
Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Bénard J, Douc-Rasy S, Cappellen D. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res 2008; 36:4222-32. [PMID: 18583365 PMCID: PMC2490757 DOI: 10.1093/nar/gkn394] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
MYCN activation, mainly by gene amplification, is one of the most frequent molecular events in neuroblastoma (NB) oncogenesis, and is associated with increased malignancy and decreased neuronal differentiation propensity. The frequency of concomitant loss of heterozygosity at the 1p36.3 locus, which harbours the p53 anti-oncogene homologue TP73, indicates that MYCN and p73 alterations may cooperate in the pathogenesis of NB. We have previously shown that p73 isoforms are deregulated in NB tumours and that TAp73 co-operates synergistically with p53 for apoptosis of NB cells, whereas ΔNp73 activates the expression of neuronal differentiation genes such as BTG2. Herein, using both ectopic expression and RNA interference-mediated silencing of p73 in MYCN amplified NB cells, we show that p73α isoforms inhibit MYCN expression at both transcript and protein levels, in spite of transactivator effects on MYCN promoter. To explain this paradox, we found that TAp73α exerts negative post-transcriptional effects leading to reduced MYCN mRNA stability. RNA immunoprecipitation experiments suggest that this dominant inhibitory post-transcriptional effect could be due to an interaction between the p73 protein and MYCN mRNA, a hypothesis also raised for the regulation of certain genes by the p53 protein.
Collapse
Affiliation(s)
- Emilie Horvilleur
- Interactions Molécularies et Cancer, Unité Mixte de Recherche 8126, Centre National de Recherche Scientifique-Université Paris Sud-11, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 2006; 8:70-6. [PMID: 17159920 PMCID: PMC1796762 DOI: 10.1038/sj.embor.7400849] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2005] [Revised: 09/20/2006] [Accepted: 09/28/2006] [Indexed: 11/09/2022] Open
Abstract
The developmental and oncogenic roles of MYC proteins are well established, but the transcriptional targets mediating their functions remain elusive. Using small interfering RNA-mediated knockdown in breast and cervix carcinoma cell lines, which overexpress c-MYC, we show that c-MYC independently controls metabolism and cell proliferation, and can, depending on the cells, promote or inhibit migration. We identified new c-MYC target genes in these cell lines, and show that selective regulation of some targets correlates with the phenotypic responses of these different cell lines to c-MYC depletion. Notably, we show that a positive regulation of the WNT signalling pathway contributes to c-MYC pro-mitogenic effects in breast and cervix carcinoma cells. We also show that repression of CCL5/RANTES accounts for c-MYC anti-migratory effects in specific breast cancer cells. Our combined genomic and phenotypic analysis indicates that c-MYC functions are cellular-context-dependent and that selectively regulated genes are responsible for its differential properties.
Collapse
Affiliation(s)
- David Cappellen
- Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
- U 817 Institut National de la Santé et de la Recherche Médicale, Institut de Rercherches sur le Cancer de Lille, Place de Verdun, 59045 Lille Cedex, France
- UMR 8126 Centre National de la Recherche Scientifique, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
- Tel: +33 1 42 11 61 44; Fax: +33 1 42 11 54 94; E-mail:
| | - Thomas Schlange
- Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
| | - Matthieu Bauer
- U 817 Institut National de la Santé et de la Recherche Médicale, Institut de Rercherches sur le Cancer de Lille, Place de Verdun, 59045 Lille Cedex, France
- UMR 8126 Centre National de la Recherche Scientifique, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
| | - Francisca Maurer
- Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
| | - Nancy E Hynes
- Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
- Tel: +41 61 697 8107; Fax: +41 61 697 8102; E-mail:
| |
Collapse
|
40
|
Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillault A, Diez de Medina SG, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2005; 27:740-7. [PMID: 16338952 DOI: 10.1093/carcin/bgi290] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Germinal activating mutations of FGFR3 are responsible for several forms of dwarfism due to the inhibitory effect of FGFR3 on bone growth. Surprisingly, identical somatic activating mutations have been found at the somatic level in tumours: at high frequency in benign epithelial tumours (seborrheic keratosis, urothelial papilloma) and in low-grade, low-stage urothelial carcinomas, and at a lower frequency in other types of urothelial carcinoma, in cervix carcinoma, and in haematological cancer, multiple myeloma. FGFR3 exists as two isoforms, FGFR3b and FGFR3c, differs in ligand specificity and tissue expression. FGFR3b is the main form in epithelial cells and derived tumours, whereas FGFR3c is the main form in mesenchyme-derived cells and multiple myeloma. Several lines of evidence suggest that mutated FGFR3c has transforming properties. Although mutated FGFR3b is mostly found in benign epithelial tumours or carcinomas of low malignant potential, we present evidence here that mutated FGFR3b is oncogenic. All bladder tumours presenting FGFR3 mutations expressed this receptor more strongly than normal urothelium or non-mutated tumours. NIH-3T3 cells transfected with a mutated form of FGFR3b--FGFR3b-S249C, the most common mutation in bladder tumours--presented a spindle-cell morphology, grew in soft agar and gave rise to tumours when xenografted into nude mice. We identified one line of 17 bladder cell lines tested (MGH-U3) that expressed a mutated form of FGFR3b, FGFR3b-Y375C. We showed using siRNA and SU5402, an FGFR inhibitor, that the tumour properties of MGH-U3 depended on mutated receptor activity. Thus, in two different models, mutated FGFR3b presents oncogenic properties.
Collapse
Affiliation(s)
- Isabelle Bernard-Pierrot
- UMR 144, CNRS-Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, and INSERM 0337 and Service d'Urologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Paris XII, 94010 Créteil Cedex, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Chopin D, Cappellen D, Fradvanyi F, Gattegno B. [The p53 gene]. Prog Urol 2005; 15:1338-43. [PMID: 16734226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
|
42
|
Rosty C, Aubriot MH, Cappellen D, Bourdin J, Cartier I, Thiery JP, Sastre-Garau X, Radvanyi F. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer 2005; 4:15. [PMID: 15869706 PMCID: PMC1131920 DOI: 10.1186/1476-4598-4-15] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2004] [Accepted: 05/03/2005] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND We have previously reported activating mutations of the gene coding for the fibroblast growth factor receptor 3 (FGFR3) in invasive cervical carcinoma. To further analyze the role of FGFR3 in cervical tumor progression, we extended our study to screen a total of 75 invasive tumors and 80 cervical intraepithelial neoplasias (40 low-grade and 40 high-grade lesions). RESULTS Using single strand conformation polymorphism (SSCP) followed by DNA sequencing, we found FGFR3 mutation (S249C in all cases) in 5% of invasive cervical carcinomas and no mutation in intraepithelial lesions. These results suggest that, unlike in bladder carcinoma, FGFR3 mutation does not or rarely occur in non invasive lesions. Compared to patients with wildtype FGFR3 tumor, patients with S249C FGFR3 mutated tumors were older (mean age 64 vs. 49.4 years, P = 0.02), and were more likely to be associated with a non-16/18 HPV type in their tumor. Gene expression analysis demonstrated that FGFR3 mutated tumors were associated with higher FGFR3b mRNA expression levels compared to wildtype FGFR3 tumors. Supervised analysis of Affymetrix expression data identified a significant number of genes specifically differentially expressed in tumors with respect to FGFR3 mutation status. CONCLUSION This study suggest that tumors with FGFR3 mutation appear to have distinctive clinical and biological characteristics that may help in defining a population of patients for FGFR3 mutation screening.
Collapse
Affiliation(s)
- Christophe Rosty
- Département de Pathologie, Institut Curie, Section Médicale, 26 rue d'Ulm, 75248 Paris Cedex 05, France
- UMR 144, CNRS – Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | - Marie-Hélène Aubriot
- UMR 144, CNRS – Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | - David Cappellen
- UMR 144, CNRS – Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | - Jérôme Bourdin
- UMR 144, CNRS – Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | - Isabelle Cartier
- Laboratoire du Dr René Cartier, 20 rue des Cordelières, 75013 Paris, France
| | - Jean Paul Thiery
- UMR 144, CNRS – Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | - Xavier Sastre-Garau
- Département de Pathologie, Institut Curie, Section Médicale, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | - François Radvanyi
- UMR 144, CNRS – Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| |
Collapse
|
43
|
Zamurovic N, Cappellen D, Rohner D, Susa M. Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 2004; 279:37704-15. [PMID: 15178686 DOI: 10.1074/jbc.m403813200] [Citation(s) in RCA: 184] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
To examine early events in osteoblast differentiation, we analyzed the expression of about 9,400 genes in the murine MC3T3 cell line, whose robust differentiation was documented cytochemically and molecularly. The cells were stimulated for 1 and 3 days with the osteogenic stimulus containing bone morphogenic protein 2. Total RNA was extracted and analyzed by Affymetrix GeneChip oligonucleotide arrays. A regulated expression of 394 known genes and 295 expressed sequence tags was detected. The sensitivity and reliability of detection by microarrays was shown by confirming the expression pattern for 20 genes by radioactive quantitative reverse transcription-PCR. Functional classification of regulated genes was performed, defining the groups of regulated growth factors, receptors, and transcription factors. The most interesting finding was concomitant activation of transforming growth factor-beta, Wnt, and Notch signaling pathways, confirmed by strong up-regulation of their target genes by PCR. The transforming growth factor-beta pathway is activated by stimulated production of the growth factor itself, while the exact mechanism of Wnt and Notch activation remains elusive. We showed that bone morphogenic protein 2 stimulated expression of Hey1, a direct Notch target gene, in mouse MC3T3 and C2C12 cells, in human mesenchymal cells, and in mouse calvaria. Small interfering RNA-mediated inhibition of Hey1 induction led to an increase in osteoblast matrix mineralization, suggesting that Hey1 is a negative regulator of osteoblast maturation. This negative regulation is apparently achieved via interaction with Runx2: Hey1 completely abrogated Runx2 transcriptional activity. These findings identify the Notch-Hey1 pathway as a negative regulator of osteoblast differentiation/maturation, which is a completely novel aspect of osteogenesis and could point to possible new targets for bone anabolic agents.
Collapse
Affiliation(s)
- Natasa Zamurovic
- Arthritis and Bone Metabolism/Gastrointestinal Disease Area, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
| | | | | | | |
Collapse
|
44
|
Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2004; 2:6. [PMID: 15025786 PMCID: PMC394349 DOI: 10.1186/1479-5876-2-6] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2004] [Accepted: 03/16/2004] [Indexed: 11/10/2022] Open
Abstract
Osteoclasts are cells of hematopoietic origin with a unique property of dissolving bone; their inhibition is a principle for treatment of diseases of bone loss. Protocols for generation of human osteoclasts in vitro have been described, but they often result in cells of low activity, raising questions on cell phenotype and suitability of such assays for screening of bone resorption inhibitors. Here we describe an optimized protocol for the production of stable amounts of highly active human osteoclasts. Mononuclear cells were isolated from human peripheral blood by density centrifugation, seeded at 600,000 cells per 96-well and cultured for 17 days in alpha-MEM medium, supplemented with 10% of selected fetal calf serum, 1 microM dexamethasone and a mix of macrophage-colony stimulating factor (M-CSF, 25 ng/ml), receptor activator of NFkappaB ligand (RANKL, 50 ng/ml), and transforming growth factor-beta1 (TGF-beta1, 5 ng/ml). Thus, in addition to widely recognized osteoclast-generating factors M-CSF and RANKL, other medium supplements and lengthy culture times were necessary. This assay reliably detected inhibition of osteoclast formation (multinucleated cells positive for tartrate-resistant acid phosphatase) and activity (resorbed area and collagen fragments released from bone slices) in dose response curves with several classes of bone resorption inhibitors. Therefore, this assay can be applied for monitoring bone-resorbing activity of novel drugs and as an clinical test for determining the capacity of blood cells to generate bone-resorbing osteoclasts. Isolation of large quantities of active human osteoclast mRNA and protein is also made possible by this assay.
Collapse
Affiliation(s)
- Mira Susa
- Arthritis and Bone Metabolism Disease Area, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, CH-4002 Basel, Switzerland
| | - Ngoc-Hong Luong-Nguyen
- Arthritis and Bone Metabolism Disease Area, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, CH-4002 Basel, Switzerland
| | - David Cappellen
- Arthritis and Bone Metabolism Disease Area, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, CH-4002 Basel, Switzerland
| | - Natasa Zamurovic
- Arthritis and Bone Metabolism Disease Area, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, CH-4002 Basel, Switzerland
| | - Rainer Gamse
- Arthritis and Bone Metabolism Disease Area, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, CH-4002 Basel, Switzerland
| |
Collapse
|
45
|
Roulland S, Lebailly P, Roussel G, Briand M, Cappellen D, Pottier D, Hardouin A, Troussard X, Bastard C, Henry-Amar M, Gauduchon P. BCL-2/JH translocation in peripheral blood lymphocytes of unexposed individuals: lack of seasonal variations in frequency and molecular features. Int J Cancer 2003; 104:695-8. [PMID: 12640675 DOI: 10.1002/ijc.10975] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BCL-2/J(H) rearrangement has been proposed as a biomarker for evaluating the genotoxicity of occupational and environmental exposures. Available data on time-related modification of this rearrangement in peripheral blood lymphocytes in unexposed healthy individuals is scarce. We investigated the characteristics of BCL-2/J(H) rearrangements in 33 adults unexposed to genotoxins at 2 seasonal time points: winter and spring. BCL-2/J(H) rearrangement was detected in 79% of individuals (detection limit = 8.48 x 10(-8)). Its frequency ranged from <1 to 40 translocations per million lymphocytes with a significant (p = 0.04) positive correlation with age. No significant modifications of BCL-2/J(H) rearrangement frequency or in the number of clones harboring this rearrangement were observed according the 2 time points. No obvious influence of season-related environmental factors on frequency or molecular features of BCL-2/J(H) rearrangements was found in this population suggesting that this would not be a confounding factor.
Collapse
Affiliation(s)
- Sandrine Roulland
- Laboratoire de Cancérologie Expérimentale, Centre François Baclesse, Caen, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Cappellen D, Luong-Nguyen NH, Bongiovanni S, Grenet O, Wanke C, Susa M. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 2002; 277:21971-82. [PMID: 11923298 DOI: 10.1074/jbc.m200434200] [Citation(s) in RCA: 148] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Cytokines macrophage colony stimulating factor (M-CSF) and the receptor activator of NFkappaB ligand (RANKL) induce differentiation of bone marrow hematopoietic precursor cells into bone-resorbing osteoclasts without the requirement for stromal cells of mesenchymal origin. We used this recently described mouse cell system and oligonucleotide microarrays representing about 9,400 different genes to analyze gene expression in hematopoietic cells undergoing differentiation to osteoclasts. The ability of microarrays to detect the genes of interest was validated by showing expression and expected regulation of several osteoclast marker genes. In total 750 known transcripts were up-regulated by > or =2-fold, and 91% of them at an early time in culture, suggesting that almost the whole differentiation program is defined already in pre-osteoclasts. As expected, M-CSF alone induced the receptor for RANKL (RANK), but also, unexpectedly, other RANK/NFkappaB pathway components (TRAF2A, PI3-kinase, MEKK3, RIPK1), providing a molecular explanation for the synergy of M-CSF and RANKL. Furthermore, interleukins, interferons, and their receptors (IL-1alpha, IL-18, IFN-beta, IL-11Ralpha2, IL-6/11R gp130, IFNgammaR) were induced by M-CSF. Although interleukins are thought to regulate osteoclasts via modulation of M-CSF and RANKL expression in stromal cells, we showed that a mix of IL-1, IL-6, and IL-11 directly increased the activity of osteoclasts by 8.5-fold. RANKL induced about 70 novel target genes, including chemokines and growth factors (RANTES (regulated on activation, normal T cell expressed and secreted), PDGFalpha, IGF1), histamine, and alpha1A-adrenergic receptors, and three waves of distinct receptors, transcription factors, and signaling molecules. In conclusion, M-CSF induced genes necessary for a direct response to RANKL and interleukins, while RANKL directed a three-stage differentiation program and induced genes for interaction with osteoblasts and immune and nerve cells. Thus, global gene expression suggests a more dynamic role of osteoclasts in bone physiology than previously anticipated.
Collapse
Affiliation(s)
- David Cappellen
- Novartis Pharma Research, Arthritis and Bone Metabolism Therapeutic Area, CH-4002 Basel, Switzerland
| | | | | | | | | | | |
Collapse
|
47
|
Le Frère-Belda MA, Cappellen D, Daher A, Gil-Diez-de-Medina S, Besse F, Abbou CC, Thiery JP, Zafrani ES, Chopin DK, Radvanyi F. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours. Br J Cancer 2001; 85:1515-21. [PMID: 11720438 PMCID: PMC2363957 DOI: 10.1054/bjoc.2001.2106] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
The p15 gene which encodes a cyclin-dependent kinase inhibitor, is located in the 9p21 chromosomal region that is frequently deleted in human bladder transitional cell carcinomas (TCCs). The aim of the present paper is to study the potential involvement of the p15 gene in the evolution of TCCs. p15 mRNA expression was investigated by semi-quantitative RT-PCR in a series of 75 TCCs, 13 bladder cell lines and 6 normal bladder urothelia by semi-quantitative RT-PCR. p15 was expressed in the normal urothelium but p15 mRNA levels were significantly decreased in 66% of the superficial (Ta-T1) TCCs (P = 0.0015). In contrast, in muscle-invasive (T2-T4) TCCs, p15 expression differed widely between samples. p16 mRNA levels were also studied and there was no correlation between p15 and p16 mRNA levels, thus indicating that the two genes were regulated independently. Lower p15 expression in superficial tumours did not reflect a switch from quiescence to proliferative activity as normal proliferative urothelial controls did not present decreased p15 mRNA levels relative to quiescent normal urothelia. We further investigated the mechanisms underlying p15 down regulation. Homozygous deletions of the p15 gene, also involving the contiguous p16 gene, were observed in 42% of the TCCs with decreased p15 expression. No hypermethylation at multiple methylation-sensitive restriction sites in the 5;-CpG island of p15 was encountered in the remaining tumours. Our data suggest that decreased expression of p15 may be an important step in early neoplastic transformation of the urothelium and that a mechanism other than homozygous deletions or hypermethylation, may be involved in p15 down regulation.
Collapse
Affiliation(s)
- M A Le Frère-Belda
- Service d'Anatomie et de Cytologie Pathologiques, Centre Hospitalier Universitaire Henri Mondor, 94010 Créteil Cedex, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Chopin D, Cappellen D, Fradvanyi F, Gattegno B. [Fundamental bases of urothelial carcinogenesis]. Prog Urol 2001; 11:879-924. [PMID: 11769084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
49
|
Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, Ferry G, Tucker G, Poupon MF, Chopin D, Thiery JP, Radvanyi F. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999; 18:7234-43. [PMID: 10602477 DOI: 10.1038/sj.onc.1203186] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
FGFRs (fibroblast growth factor receptors) are encoded by four genes (FGFR1-4). Alternative splicing results in various receptor isoforms. The FGFR2-IIIb variant is present in a wide variety of epithelia, including the bladder epithelium. Recently, we have shown that FGFR2-IIIb is downregulated in a subset of transitional cell carcinomas of the bladder, and that this downregulation is associated with a poor prognosis. We investigated possible tumour suppressive properties of FGFR2-IIIb by transfecting two human bladder tumour cell lines, J82 and T24, which have no endogenous FGFR2-IIIb expression, with FGFR2-IIIb cDNA. No stable clones expressing FGFR2-IIIb were isolated with the J82 cell line. For the T24 cell line, stable transfectants expressing FGFR2-IIIb had reduced growth in vitro and formed fewer tumours in nude mice which, in addition, grew more slowly. The potential mechanisms leading to decreased FGFR2-IIIb mRNA levels were also investigated. The 5' region of the human FGFR2 gene was isolated and found to contain a CpG island which was partially methylated in more than half the cell lines and tumours which do not express FGFR2-IIIb. No homozygous deletion was identified in any of the tumours or cell lines with reduced levels of FGFR2-IIIb. Mutational analysis of the entire coding region of FGFR2-IIIb at the transcript level was performed in 33 bladder tumours. In addition to normal FGFR2-IIIb mRNA, abnormal transcripts were detected in two tumour samples. These abnormal mRNAs resulted from exon skipping which affected the region encoding the kinase domain. Altogether, these results show that FGFR2-IIIb has tumour growth suppressive properties in bladder carcinomas and suggest possible mechanisms of FGFR2 gene inactivation.
Collapse
Affiliation(s)
- D Ricol
- UMR 144, Centre National de la Recherche Scientifique, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23:18-20. [PMID: 10471491 DOI: 10.1038/12615] [Citation(s) in RCA: 503] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- D Cappellen
- Laboratoire de Morphogenèse Cellulaire et Progression Tumorale, UMR 144, Centre National de la Recherche Scientifique, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | | | | | | | | | | | | | | | | |
Collapse
|